"trial_id","criterion_type","ad_domain","clinical_concept","operator","value_lower","value_upper","units","diagnostic_framework","severity_stage","source_sentence","temporal_scope","evidence_type","certainty"
"NCT01767311","inclusion","other","MCI diagnosis","NA","NA","NA","NA","NIA-AA","MCI due to AD","Subjects who meet the National Institute of Aging - Alzheimer's Association (NIA-AA) core clinical criteria for mild cognitive impairment due to Alzheimer's disease - intermediate likelihood","NA","clinical_exam","must"
"NCT01767311","inclusion","global_impairment","CDR Memory Box score",">=","0.5","NA","score","NA","NA","Subjects who have a CDR score of 0.5 and a Memory Box score of 0.5 or greater at Screening and Baseline","at screening","clinical_exam","must"
"NCT01767311","inclusion","cognition","Subjective memory decline","history/presence of","NA","NA","NA","NA","NA","Subjects who report a history of subjective memory decline with gradual onset and slow progression over the last one year before Screening; MUST be corroborated by an informant","NA","questionnaire","must"
"NCT01767311","inclusion","demographics","Age","NA","NA","NA","NA","NA","NA","Subjects who report a history of subjective memory decline with gradual onset and slow progression over the last one year before Screening; MUST be corroborated by an informant","NA","questionnaire","must"
"NCT01767311","inclusion","other","AD dementia diagnosis","NA","NA","NA","NA","NIA-AA","probable AD dementia","Subjects who meet the NIA-AA core clinical criteria for probable Alzheimer's disease dementia","NA","clinical_exam","must"
"NCT01767311","inclusion","global_impairment","CDR Memory Box score",">=","0.5","NA","score","NA","NA","Subjects who have a CDR score of 0.5-1.0 and a Memory Box score of 0.5 or greater at Screening and Baseline","at screening","clinical_exam","must"
"NCT01767311","inclusion","cognition","Objective cognitive impairment","NA","NA","NA","NA","NA","NA","Subjects with objective impairment in episodic memory as indicated by at least 1 standard deviation below age-adjusted mean in the Wechsler Memory Scale - IV Logical Memory II (WMS-IV LMII):","NA","cognitive_test","must"
"NCT01767311","inclusion","demographics","Age","between","50","64","years","NA","NA","Less than or equal to 15 for age 50 to 64 years","NA","NA","must"
"NCT01767311","inclusion","demographics","Age","between","65","69","years","NA","NA","Less than or equal to 12 for age 65 to 69 years","NA","NA","must"
"NCT01767311","inclusion","demographics","Age","between","70","74","years","NA","NA","Less than or equal to 11 for age 70 to 74 years","NA","NA","must"
"NCT01767311","inclusion","demographics","Age","between","75","79","years","NA","NA","Less than or equal to 9 for age 75 to 79 years","NA","NA","must"
"NCT01767311","inclusion","demographics","Age","between","80","90","years","NA","NA","Less than or equal to 7 for age 80 to 90 years","NA","NA","must"
"NCT01767311","inclusion","imaging","Amyloid PET","positive","NA","NA","NA","NA","NA","Positive amyloid load as indicated by PET or CSF assessment","NA","PET","must"
"NCT01767311","inclusion","biomarkers","CSF biomarkers","NA","NA","NA","NA","NA","NA","Positive amyloid load as indicated by PET or CSF assessment","NA","CSF","must"
"NCT01767311","inclusion","imaging","PET imaging","NA","NA","NA","NA","NA","NA","PET assessment of imaging agent uptake into brain","NA","PET","must"
"NCT01767311","inclusion","biomarkers","CSF biomarkers","NA","NA","NA","NA","NA","NA","CSF assessment of Aβ(1-42)","NA","CSF","must"
"NCT01767311","inclusion","demographics","Age","between","50","90","years","NA","NA","Age between 50 and 90 years, inclusive","NA","NA","must"
"NCT01767311","inclusion","cognition","MMSE","NA","NA","NA","NA","NA","NA","Mini Mental State Examination (MMSE) score equal to or greater than 22, and equal to or less than 30, at Screening and Baseline","at screening","cognitive_test","must"
"NCT01767311","inclusion","demographics","Body mass index","NA","NA","NA","NA","NA","NA","Body Mass Index (BMI) greater than 17 and less than 35 at Screening or Baseline","at screening","clinical_exam","must"
"NCT01767311","inclusion","demographics","Sex/pregnancy","negative","NA","NA","NA","NA","NA","Females must not be lactating or pregnant at Screening or Baseline (as documented by a negative beta-human chorionic gonadotropin assay \[ß-hCG\]). A separate baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug.","at screening","NA","must not"
"NCT01767311","inclusion","medications","Concomitant AD medications","NA","NA","NA","NA","NA","NA","Subjects on acetylcholinesterase inhibitor or memantine therapy or both for AD must be on a stable dose for at least 12 weeks prior to Baseline. Treatment naive subjects can be entered into the study. Unless otherwise stated, subjects must have been on stable doses of all other permitted concomitant medications (ie, non-AD related) for at least 4 weeks prior to Baseline.","prior to baseline","NA","must"
"NCT01767311","inclusion","medications","Concomitant AD medications","NA","NA","NA","NA","NA","NA","Subjects on acetylcholinesterase inhibitor or memantine therapy or both for AD must be on a stable dose for at least 12 weeks prior to Baseline. Treatment naive subjects can be entered into the study. Unless otherwise stated, subjects must have been on stable doses of all other permitted concomitant medications (ie, non-AD related) for at least 4 weeks prior to Baseline.","prior to baseline","NA","must"
"NCT01767311","inclusion","safety_labs","Safety labs/organ function","NA","NA","NA","NA","NA","NA","Subjects on acetylcholinesterase inhibitor or memantine therapy or both for AD must be on a stable dose for at least 12 weeks prior to Baseline. Treatment naive subjects can be entered into the study. Unless otherwise stated, subjects must have been on stable doses of all other permitted concomitant medications (ie, non-AD related) for at least 4 weeks prior to Baseline.","prior to baseline","lab_test","must"
"NCT01767311","inclusion","study_operations","Study partner","NA","NA","NA","NA","NA","NA","Subjects must have identified caregivers/informants","NA","NA","must"
"NCT01767311","inclusion","study_operations","Informed consent","consent to","NA","NA","NA","NA","NA","Subjects must provide written informed consent","NA","NA","must"
"NCT01767311","inclusion","other","NA","NA","NA","NA","NA","NA","NA","Subjects who have completed Visit 42 (Week 79) of the Core Study or who discontinued study drug during the Core Study due to any of the following reasons:","NA","NA","must"
"NCT01767311","inclusion","other","NA","NA","NA","NA","NA","NA","NA","Alzheimer's Related Imaging Abnormality-Edema (ARIA-E)","NA","NA","must"
"NCT01767311","inclusion","other","NA","NA","NA","NA","NA","NA","NA","Amyloid related imaging abnormality hemorrhage (ARIA-H) (superficial siderosis, macrohemorrhage, or symptomatic microhemorrhage)","NA","NA","must"
"NCT01767311","inclusion","other","NA","NA","NA","NA","NA","NA","NA","Prohibited or restricted medications that were prohibited during Core Study conduct but are no longer prohibited in the Extension Phase","NA","NA","must"
"NCT01767311","inclusion","other","NA","positive","NA","NA","NA","NA","NA","Subjects who were APOE4 positive and receiving treatment with lecanemab 10 mg/kg biweekly","NA","NA","must"
"NCT01767311","inclusion","other","NA","NA","NA","NA","NA","NA","NA","Any reason for discontinuation not related to prohibited medications, including any AE that was considered not related to study drug, and that was not severe or life-threatening","NA","NA","must"
"NCT01767311","inclusion","study_operations","Study partner","able/willing","NA","NA","NA","NA","NA","Must continue to have an identified caregiver or informant who is willing and able to provide follow-up information on the subject throughout the course of the Extension Phase","NA","NA","must"
"NCT01767311","inclusion","study_operations","Informed consent","consent to","NA","NA","NA","NA","NA","Provide written informed consent. If a subject lacks capacity to consent in the investigator's opinion, the subject's assent should be obtained, if required in accordance with local laws, regulations and customs, plus the written informed consent of a legal representative should be obtained (capacity to consent and definition of legal representative should be determined in accordance with applicable local laws and regulations).","NA","NA","should"
"NCT01767311","inclusion","other","NA","able/willing","NA","NA","NA","NA","NA","Must be able to physically attend clinic visits and be willing and able to comply with all aspects of the protocol","NA","NA","must"
"NCT01767311","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Any neurological condition that may be contributing to cognitive impairment above and beyond that caused by the subject's AD","NA","NA","may"
"NCT01767311","exclusion","comorbidities","Stroke/TIA history","history/presence of","NA","NA","NA","NA","NA","History of transient ischemic attacks (TIA), stroke, or seizures within 12 months of Screening","NA","clinical_exam","must not"
"NCT01767311","exclusion","comorbidities","Seizure history","NA","NA","NA","NA","NA","NA","History of transient ischemic attacks (TIA), stroke, or seizures within 12 months of Screening","NA","clinical_exam","must not"
"NCT01767311","exclusion","comorbidities","Psychiatric disorder history","history/presence of","NA","NA","NA","NA","NA","Any psychiatric diagnosis or symptoms, (e.g., hallucinations, major depression, or delusions) that could interfere with study procedures in the subject","NA","clinical_exam","must not"
"NCT01767311","exclusion","comorbidities","Geriatric Depression Scale",">=","8","NA","score","NA","NA","Geriatric Depression Scale (GDS) score ≥8 at Screening","at screening","questionnaire","must not"
"NCT01767311","exclusion","imaging","Brain MRI","absent","NA","NA","NA","NA","NA","Contraindications to MRI scanning, including cardiac pacemaker/ defibrillator, ferromagnetic metal implants, e,g., in skull and cardiac devices other than those approved as safe for use in MR scanners","NA","MRI","must not"
"NCT01767311","exclusion","imaging","Brain MRI","history/presence of","NA","NA","NA","NA","NA","Evidence of other clinically significant lesions that could indicate a dementia diagnosis other than AD on brain MRI at Screening, or other significant pathological findings on brain MRI at Screening","at screening","MRI","must not"
"NCT01767311","exclusion","imaging","Brain MRI","NA","NA","NA","NA","NA","NA","Evidence of other clinically significant lesions that could indicate a dementia diagnosis other than AD on brain MRI at Screening, or other significant pathological findings on brain MRI at Screening","at screening","MRI","must not"
"NCT01767311","exclusion","other","NA","NA","NA","NA","NA","NA","NA","A prolonged QT/QTc interval (QTc greater than 450 ms) as demonstrated by a repeated electrocardiogram (ECG)","NA","NA","must not"
"NCT01767311","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Certain other specified medical conditions","NA","NA","must not"
"NCT01767311","exclusion","comorbidities","Psychiatric disorder history","NA","NA","NA","NA","NA","NA","Severe visual or hearing impairment that would prevent the subject from performing psychometric tests accurately","NA","clinical_exam","must not"
"NCT01767311","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Subjects who discontinued from the study drug or from the Core Study for reasons other than the following:","NA","NA","must not"
"NCT01767311","exclusion","other","NA","NA","NA","NA","NA","NA","NA","ARIA-E","NA","NA","must not"
"NCT01767311","exclusion","other","NA","NA","NA","NA","NA","NA","NA","ARIA-H (superficial siderosis, macrohemorrhage, or symptomatic microhemorrhage)","NA","NA","must not"
"NCT01767311","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Prohibited or restricted medications that were prohibited during Core Study conduct but are no longer prohibited in the Extension Phase","NA","NA","must not"
"NCT01767311","exclusion","other","NA","positive","NA","NA","NA","NA","NA","Subjects who were APOE4 positive and receiving treatment with lecanemab 10 mg/kg biweekly","NA","NA","must not"
"NCT01767311","exclusion","other","NA","NA","NA","NA","NA","NA","NA","AE that was considered not related to study drug, and that was not severe or life-threatening","NA","NA","must not"
"NCT01767311","exclusion","demographics","Sex/pregnancy","NA","NA","NA","NA","NA","NA","Females of childbearing potential who do not agree to use a highly effective method of contraception","NA","NA","must"
"NCT01767311","exclusion","comorbidities","Psychiatric disorder history","NA","NA","NA","NA","NA","NA","Severe visual or hearing impairment that would prevent the subject from performing psychometric tests accurately.","NA","clinical_exam","must not"
"NCT02008357","inclusion","cognition","MMSE","between","25","30","score","NA","NA","Has a Mini-Mental State Examination (MMSE) score at screening of 25 to 30","at screening","cognitive_test","must"
"NCT02008357","inclusion","global_impairment","CDR global score","=","0","NA","score","NA","NA","Has a global Clinical Dementia Rating (CDR) scale score at screening of 0","at screening","clinical_exam","must"
"NCT02008357","inclusion","cognition","Wechsler Memory Scale Logical Memory","between","6","18","score","NA","NA","Has a Logical Memory II score at screening of 6 to 18","at screening","cognitive_test","must"
"NCT02008357","inclusion","biomarkers","Amyloid pathology","positive","NA","NA","NA","NA","NA","Has a florbetapir positron emission tomography (PET) scan that shows evidence of brain amyloid pathology at screening","at screening","NA","must"
"NCT02008357","inclusion","study_operations","Study partner","able/willing","NA","NA","NA","NA","NA","Has a study partner that is willing to participate as a source of information and has at least weekly contact with the participant (contact can be in-person, via telephone or electronic communication)","NA","NA","must"
"NCT02008357","inclusion","safety_labs","Safety labs/organ function","NA","NA","NA","NA","NA","NA","Has a study partner that is willing to participate as a source of information and has at least weekly contact with the participant (contact can be in-person, via telephone or electronic communication)","NA","lab_test","must"
"NCT02008357","exclusion","medications","Concomitant AD medications","NA","NA","NA","NA","NA","NA","Is receiving a prescription acetylcholinesterase inhibitor (AChEI) and/or memantine at screening or baseline","at screening","NA","must not"
"NCT02008357","exclusion","safety_labs","Safety labs/organ function","NA","NA","NA","NA","NA","NA","Lacks good venous access, such that intravenous drug delivery or multiple blood draws would be precluded","NA","lab_test","must not"
"NCT02008357","exclusion","safety_labs","Safety labs/organ function","NA","NA","NA","NA","NA","NA","Has current serious or unstable illness including cardiovascular, hepatic, renal, gastroenterologic, respiratory, endocrinologic, neurologic, psychiatric, immunologic, or hematologic disease or other conditions that, in the investigator's opinion, could interfere with the analyses of safety and efficacy in this study","NA","lab_test","must not"
"NCT02008357","exclusion","safety_labs","Safety labs/organ function","NA","NA","NA","NA","NA","NA","Has current serious or unstable illness including cardiovascular, hepatic, renal, gastroenterologic, respiratory, endocrinologic, neurologic, psychiatric, immunologic, or hematologic disease or other conditions that, in the investigator's opinion, could interfere with the analyses of safety and efficacy in this study","NA","lab_test","must not"
"NCT02008357","exclusion","safety_labs","Safety labs/organ function","NA","NA","NA","NA","NA","NA","Has current serious or unstable illness including cardiovascular, hepatic, renal, gastroenterologic, respiratory, endocrinologic, neurologic, psychiatric, immunologic, or hematologic disease or other conditions that, in the investigator's opinion, could interfere with the analyses of safety and efficacy in this study","NA","lab_test","must not"
"NCT02008357","exclusion","safety_labs","Safety labs/organ function","NA","NA","NA","NA","NA","NA","Has current serious or unstable illness including cardiovascular, hepatic, renal, gastroenterologic, respiratory, endocrinologic, neurologic, psychiatric, immunologic, or hematologic disease or other conditions that, in the investigator's opinion, could interfere with the analyses of safety and efficacy in this study","NA","lab_test","must not"
"NCT02008357","exclusion","safety_labs","Safety labs/organ function","NA","NA","NA","NA","NA","NA","Has current serious or unstable illness including cardiovascular, hepatic, renal, gastroenterologic, respiratory, endocrinologic, neurologic, psychiatric, immunologic, or hematologic disease or other conditions that, in the investigator's opinion, could interfere with the analyses of safety and efficacy in this study","NA","lab_test","must not"
"NCT02008357","exclusion","demographics","Age","history/presence of","NA","NA","NA","NA","NA","Has had a history within the last 5 years of a serious infectious disease affecting the brain (including neurosyphilis, meningitis, or encephalitis) or head trauma resulting in protracted loss of consciousness","NA","NA","must not"
"NCT02008357","exclusion","comorbidities","CNS infection history","NA","NA","NA","NA","NA","NA","Has had a history within the last 5 years of a serious infectious disease affecting the brain (including neurosyphilis, meningitis, or encephalitis) or head trauma resulting in protracted loss of consciousness","NA","clinical_exam","must not"
"NCT02008357","exclusion","demographics","Age","NA","NA","NA","NA","NA","NA","Has had a history within the last 5 years of a serious infectious disease affecting the brain (including neurosyphilis, meningitis, or encephalitis) or head trauma resulting in protracted loss of consciousness","NA","NA","must not"
"NCT02008357","exclusion","demographics","Age","history/presence of","NA","NA","NA","NA","NA","Has had a history within the last 5 years of a primary or recurrent malignant disease with the exception of any in situ cancer that was appropriately treated and is being appropriately monitored, such as resected cutaneous squamous cell carcinoma in situ or in situ prostate cancer with normal prostate-specific antigen post-treatment","NA","NA","must not"
"NCT02008357","exclusion","comorbidities","Malignancy","NA","NA","NA","NA","NA","NA","Has had a history within the last 5 years of a primary or recurrent malignant disease with the exception of any in situ cancer that was appropriately treated and is being appropriately monitored, such as resected cutaneous squamous cell carcinoma in situ or in situ prostate cancer with normal prostate-specific antigen post-treatment","NA","clinical_exam","must not"
"NCT02008357","exclusion","comorbidities","Malignancy","NA","NA","NA","NA","NA","NA","Has had a history within the last 5 years of a primary or recurrent malignant disease with the exception of any in situ cancer that was appropriately treated and is being appropriately monitored, such as resected cutaneous squamous cell carcinoma in situ or in situ prostate cancer with normal prostate-specific antigen post-treatment","NA","clinical_exam","must not"
"NCT02008357","exclusion","comorbidities","HIV infection","history/presence of","NA","NA","NA","NA","NA","Has a known history of human immunodeficiency virus (HIV), clinically significant multiple or severe drug allergies, or severe post-treatment hypersensitivity reactions (including, but not limited to, erythema multiforme major, linear immunoglobulin A dermatosis, toxic epidermal necrolysis, or exfoliative dermatitis)","NA","lab_test","must not"
"NCT02008357","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Is clinically judged by the investigator to be at serious risk for suicide","NA","NA","must not"
"NCT02008357","exclusion","demographics","Age","history/presence of","NA","NA","NA","DSM","NA","Has a history within the past 2 years of major depression or bipolar disorder as defined by the most current version of the Diagnostic and Statistical Manual of Mental Disorders (DSM)","within the past 2 years","NA","must not"
"NCT02008357","exclusion","comorbidities","Psychiatric disorder history","NA","NA","NA","NA","DSM","NA","Has a history within the past 2 years of major depression or bipolar disorder as defined by the most current version of the Diagnostic and Statistical Manual of Mental Disorders (DSM)","within the past 2 years","clinical_exam","must not"
"NCT02008357","exclusion","demographics","Age","NA","NA","NA","NA","DSM","NA","Has a history within the past 2 years of major depression or bipolar disorder as defined by the most current version of the Diagnostic and Statistical Manual of Mental Disorders (DSM)","within the past 2 years","NA","must not"
"NCT02008357","exclusion","demographics","Age","history/presence of","NA","NA","NA","DSM","NA","Has a history within the past 5 years of chronic alcohol or drug abuse/dependence as defined by the most current version of the DSM","within the past 5 years","NA","must not"
"NCT02008357","exclusion","lifestyle","Alcohol/substance use","NA","NA","NA","NA","DSM","NA","Has a history within the past 5 years of chronic alcohol or drug abuse/dependence as defined by the most current version of the DSM","within the past 5 years","questionnaire","must not"
"NCT02008357","exclusion","other","NA","NA","NA","NA","NA","NA","NA","All participants who complete the placebo-controlled period will be allowed to continue into the open-label period","NA","NA","must not"
"NCT02477800","inclusion","other","MCI diagnosis","NA","NA","NA","NA","NA","MCI due to AD","Must meet all of the following clinical criteria for MCI due to AD or mild AD and must have:","NA","clinical_exam","must"
"NCT02477800","inclusion","global_impairment","CDR global score","NA","NA","NA","NA","NA","NA","A Clinical Dementia Rating (CDR)-Global Score of 0.5.","NA","clinical_exam","must"
"NCT02477800","inclusion","cognition","Objective cognitive impairment","NA","NA","NA","NA","NA","NA","Objective evidence of cognitive impairment at screening","at screening","cognitive_test","must"
"NCT02477800","inclusion","cognition","MMSE","between","24","30","score","NA","NA","An MMSE score between 24 and 30 (inclusive)","NA","cognitive_test","must"
"NCT02477800","inclusion","imaging","Amyloid PET","positive","NA","NA","NA","NA","NA","Must have a positive amyloid Positron Emission Tomography (PET) scan","NA","PET","must"
"NCT02477800","inclusion","genetics","APOE genotype","consent to","NA","NA","NA","NA","NA","Must consent to apolipoprotein E (ApoE) genotyping","NA","genetic_test","must"
"NCT02477800","inclusion","safety_labs","Safety labs/organ function","NA","NA","NA","NA","NA","NA","If using drugs to treat symptoms related to AD, doses must be stable for at least 8 weeks prior to screening visit 1","prior to screening","lab_test","must"
"NCT02477800","inclusion","study_operations","Study partner","NA","NA","NA","NA","NA","NA","Must have a reliable informant or caregiver","NA","NA","must"
"NCT02477800","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Any medical or neurological condition (other than Alzheimer's Disease) that might be a contributing cause of the subject's cognitive impairment","NA","NA","must not"
"NCT02477800","exclusion","comorbidities","Stroke/TIA history","NA","NA","NA","NA","NA","NA","Have had a stroke or Transient Ischemic Attack (TIA) or unexplained loss of consciousness in the past 1 year","NA","clinical_exam","must not"
"NCT02477800","exclusion","comorbidities","Stroke/TIA history","NA","NA","NA","NA","NA","NA","Have had a stroke or Transient Ischemic Attack (TIA) or unexplained loss of consciousness in the past 1 year","NA","clinical_exam","must not"
"NCT02477800","exclusion","demographics","Age","NA","NA","NA","NA","NA","NA","Have had a stroke or Transient Ischemic Attack (TIA) or unexplained loss of consciousness in the past 1 year","NA","NA","must not"
"NCT02477800","exclusion","safety_labs","Safety labs/organ function","history/presence of","NA","NA","NA","NA","NA","Clinically significant unstable psychiatric illness in past 6 months","NA","lab_test","must not"
"NCT02477800","exclusion","demographics","Age","history/presence of","NA","NA","NA","NA","NA","History of unstable angina, myocardial infarction, advanced chronic heart failure, or clinically significant conduction abnormalities within 1 year prior to Screening","prior to screening","NA","must not"
"NCT02477800","exclusion","safety_labs","Safety labs/organ function","NA","NA","NA","NA","NA","NA","Indication of impaired renal or liver function","NA","lab_test","must not"
"NCT02477800","exclusion","comorbidities","HIV infection","NA","NA","NA","NA","NA","NA","Have human immunodeficiency virus (HIV) infection","NA","lab_test","must not"
"NCT02477800","exclusion","safety_labs","Safety labs/organ function","NA","NA","NA","NA","NA","NA","Have a significant systematic illness or infection in past 30 days","NA","lab_test","must not"
"NCT02477800","exclusion","safety_labs","Safety labs/organ function","NA","NA","NA","NA","NA","NA","Have a significant systematic illness or infection in past 30 days","NA","lab_test","must not"
"NCT02477800","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Relevant brain hemorrhage, bleeding disorder and cerebrovascular abnormalities","NA","NA","must not"
"NCT02477800","exclusion","imaging","Brain MRI","absent","NA","NA","NA","NA","NA","Any contraindications to brain magnetic resonance imaging (MRI) or PET scans","NA","MRI","must not"
"NCT02477800","exclusion","imaging","PET imaging","NA","NA","NA","NA","NA","NA","Any contraindications to brain magnetic resonance imaging (MRI) or PET scans","NA","PET","must not"
"NCT02477800","exclusion","lifestyle","Alcohol/substance use","NA","NA","NA","NA","NA","NA","Alcohol or substance abuse in past 1 year","NA","questionnaire","must not"
"NCT02477800","exclusion","demographics","Age","NA","NA","NA","NA","NA","NA","Alcohol or substance abuse in past 1 year","NA","NA","must not"
"NCT02477800","exclusion","medications","Anticoagulant/antiplatelet use","NA","NA","NA","NA","NA","NA","Taking blood thinners (except for aspirin at a prophylactic dose or less)","NA","NA","must not"
"NCT02477800","exclusion","other","NA","NA","NA","NA","NA","NA","NA","NOTE: Other protocol defined Inclusion/Exclusion criteria may apply","NA","NA","may"
"NCT02484547","inclusion","other","MCI diagnosis","NA","NA","NA","NA","NA","MCI due to AD","Must meet all of the following clinical criteria for MCI due to AD or mild AD and must have:","NA","clinical_exam","must"
"NCT02484547","inclusion","global_impairment","CDR global score","NA","NA","NA","NA","NA","NA","A Clinical Dementia Rating (CDR)-Global Score of 0.5.","NA","clinical_exam","must"
"NCT02484547","inclusion","cognition","Objective cognitive impairment","NA","NA","NA","NA","NA","NA","Objective evidence of cognitive impairment at screening","at screening","cognitive_test","must"
"NCT02484547","inclusion","cognition","MMSE","between","24","30","score","NA","NA","An MMSE score between 24 and 30 (inclusive)","NA","cognitive_test","must"
"NCT02484547","inclusion","imaging","Amyloid PET","positive","NA","NA","NA","NA","NA","Must have a positive amyloid Positron Emission Tomography (PET) scan","NA","PET","must"
"NCT02484547","inclusion","genetics","APOE genotype","consent to","NA","NA","NA","NA","NA","Must consent to apolipoprotein E (ApoE) genotyping","NA","genetic_test","must"
"NCT02484547","inclusion","safety_labs","Safety labs/organ function","NA","NA","NA","NA","NA","NA","If using drugs to treat symptoms related to AD, doses must be stable for at least 8 weeks prior to screening visit 1","prior to screening","lab_test","must"
"NCT02484547","inclusion","study_operations","Study partner","NA","NA","NA","NA","NA","NA","Must have a reliable informant or caregiver","NA","NA","must"
"NCT02484547","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Any medical or neurological condition (other than Alzheimer's Disease) that might be a contributing cause of the subject's cognitive impairment","NA","NA","must not"
"NCT02484547","exclusion","comorbidities","Stroke/TIA history","NA","NA","NA","NA","NA","NA","Have had a stroke or Transient Ischemic Attack (TIA) or unexplained loss of consciousness in the past 1 year","NA","clinical_exam","must not"
"NCT02484547","exclusion","comorbidities","Stroke/TIA history","NA","NA","NA","NA","NA","NA","Have had a stroke or Transient Ischemic Attack (TIA) or unexplained loss of consciousness in the past 1 year","NA","clinical_exam","must not"
"NCT02484547","exclusion","demographics","Age","NA","NA","NA","NA","NA","NA","Have had a stroke or Transient Ischemic Attack (TIA) or unexplained loss of consciousness in the past 1 year","NA","NA","must not"
"NCT02484547","exclusion","safety_labs","Safety labs/organ function","history/presence of","NA","NA","NA","NA","NA","Clinically significant unstable psychiatric illness in past 6 months","NA","lab_test","must not"
"NCT02484547","exclusion","demographics","Age","history/presence of","NA","NA","NA","NA","NA","History of unstable angina, myocardial infarction, advanced chronic heart failure, or clinically significant conduction abnormalities within 1 year prior to Screening","prior to screening","NA","must not"
"NCT02484547","exclusion","safety_labs","Safety labs/organ function","NA","NA","NA","NA","NA","NA","Indication of impaired renal or liver function","NA","lab_test","must not"
"NCT02484547","exclusion","comorbidities","HIV infection","NA","NA","NA","NA","NA","NA","Have human immunodeficiency virus (HIV) infection","NA","lab_test","must not"
"NCT02484547","exclusion","safety_labs","Safety labs/organ function","NA","NA","NA","NA","NA","NA","Have a significant systematic illness or infection in past 30 days","NA","lab_test","must not"
"NCT02484547","exclusion","safety_labs","Safety labs/organ function","NA","NA","NA","NA","NA","NA","Have a significant systematic illness or infection in past 30 days","NA","lab_test","must not"
"NCT02484547","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Relevant brain hemorrhage, bleeding disorder and cerebrovascular abnormalities","NA","NA","must not"
"NCT02484547","exclusion","imaging","Brain MRI","absent","NA","NA","NA","NA","NA","Any contraindications to brain magnetic resonance imaging (MRI) or PET scans","NA","MRI","must not"
"NCT02484547","exclusion","imaging","PET imaging","NA","NA","NA","NA","NA","NA","Any contraindications to brain magnetic resonance imaging (MRI) or PET scans","NA","PET","must not"
"NCT02484547","exclusion","lifestyle","Alcohol/substance use","NA","NA","NA","NA","NA","NA","Alcohol or substance abuse in past 1 year","NA","questionnaire","must not"
"NCT02484547","exclusion","demographics","Age","NA","NA","NA","NA","NA","NA","Alcohol or substance abuse in past 1 year","NA","NA","must not"
"NCT02484547","exclusion","medications","Anticoagulant/antiplatelet use","NA","NA","NA","NA","NA","NA","Taking blood thinners (except for aspirin at a prophylactic dose or less)","NA","NA","must not"
"NCT02484547","exclusion","other","NA","NA","NA","NA","NA","NA","NA","NOTE: Other protocol defined Inclusion/Exclusion criteria may apply","NA","NA","may"
"NCT03443973","inclusion","other","AD dementia diagnosis","NA","NA","NA","NA","NIA-AA","prodromal AD","Meets National Institute on Aging/Alzheimer's Association (NIAAA) core clinical criteria for probable AD dementia or prodromal AD (consistent with the NIAAA diagnostic criteria and guidelines for mild cognitive impairment)","NA","clinical_exam","must"
"NCT03443973","inclusion","other","MCI diagnosis","NA","NA","NA","NA","NIA-AA","prodromal AD","Meets National Institute on Aging/Alzheimer's Association (NIAAA) core clinical criteria for probable AD dementia or prodromal AD (consistent with the NIAAA diagnostic criteria and guidelines for mild cognitive impairment)","NA","clinical_exam","must"
"NCT03443973","inclusion","other","MCI diagnosis","NA","NA","NA","NA","NIA-AA","prodromal AD","Meets National Institute on Aging/Alzheimer's Association (NIAAA) core clinical criteria for probable AD dementia or prodromal AD (consistent with the NIAAA diagnostic criteria and guidelines for mild cognitive impairment)","NA","clinical_exam","must"
"NCT03443973","inclusion","imaging","Amyloid PET","positive","NA","NA","NA","NA","NA","Evidence of the AD pathological process, as confirmed by CSF tau/A-beta42or amyloid PET scan","NA","PET","must"
"NCT03443973","inclusion","other","NA","NA","NA","NA","NA","NA","NA","Demonstrated abnormal memory function","NA","NA","must"
"NCT03443973","inclusion","cognition","MMSE",">=","22","NA","score","NA","NA","MMSE score greater than or equal to 22 (≥ 22)","NA","cognitive_test","must"
"NCT03443973","inclusion","global_impairment","CDR global score","NA","NA","NA","NA","NA","NA","Clinical dementia rating-global score (CDR-GS) of 0.5 or 1.0","NA","clinical_exam","must"
"NCT03443973","inclusion","global_impairment","CDR global score","NA","NA","NA","NA","NA","NA","Clinical dementia rating-global score (CDR-GS) of 0.5 or 1.0","NA","clinical_exam","must"
"NCT03443973","inclusion","demographics","Age","able/willing","NA","NA","NA","NA","NA","Availability of a reliable study partner who accepts to participate in study procedures throughout the 2 years duration of study","NA","NA","must"
"NCT03443973","inclusion","medications","Concomitant AD medications","NA","NA","NA","NA","NA","NA","If receiving symptomatic AD medications, the dosing regimen must have been stable for 3 months prior to screening and until randomization","prior to screening","NA","must"
"NCT03443973","inclusion","other","NA","NA","NA","NA","NA","NA","NA","For enrollment in the China extension, patients must have residence in mainland China, Hong Kong, or Taiwan and be of Chinese ancestry","NA","NA","must"
"NCT03443973","inclusion","demographics","Sex/pregnancy","NA","NA","NA","NA","NA","NA","For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods","NA","NA","must"
"NCT03443973","inclusion","study_operations","Reproductive/blood donation","NA","NA","NA","NA","NA","NA","For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods","NA","NA","must"
"NCT03443973","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Any evidence of a condition other than AD that may affect cognition","NA","NA","may"
"NCT03443973","exclusion","comorbidities","Psychiatric disorder history","history/presence of","NA","NA","NA","NA","NA","History of schizophrenia, schizoaffective disorder, major depression, or bipolar disorder","NA","clinical_exam","must not"
"NCT03443973","exclusion","comorbidities","Stroke/TIA history","history/presence of","NA","NA","NA","NA","NA","History or presence of clinically evident systemic vascular disease that in the opinion of the investigator has the potential to affect cognitive function","NA","clinical_exam","must not"
"NCT03443973","exclusion","other","NA","history/presence of","NA","NA","NA","NA","NA","History or presence of clinically evident cerebrovascular disease","NA","NA","must not"
"NCT03443973","exclusion","other","NA","history/presence of","NA","NA","NA","NA","NA","History or presence of posterior reversible encephalopathy syndrome","NA","NA","must not"
"NCT03443973","exclusion","safety_labs","Safety labs/organ function","history/presence of","NA","NA","NA","NA","NA","History or presence of any stroke with clinical symptoms within the past 12 months, or documented history within the last 6 months of an acute event that is consistent with a transient ischemic attack","within the past 12 months","lab_test","must not"
"NCT03443973","exclusion","safety_labs","Safety labs/organ function","history/presence of","NA","NA","NA","NA","NA","History or presence of any stroke with clinical symptoms within the past 12 months, or documented history within the last 6 months of an acute event that is consistent with a transient ischemic attack","within the past 12 months","lab_test","must not"
"NCT03443973","exclusion","safety_labs","Safety labs/organ function","history/presence of","NA","NA","NA","NA","NA","History or presence of any stroke with clinical symptoms within the past 12 months, or documented history within the last 6 months of an acute event that is consistent with a transient ischemic attack","within the past 12 months","lab_test","must not"
"NCT03443973","exclusion","other","NA","history/presence of","NA","NA","NA","NA","NA","History of severe, clinically significant CNS trauma","NA","NA","must not"
"NCT03443973","exclusion","comorbidities","Stroke/TIA history","history/presence of","NA","NA","NA","NA","NA","History or presence of intracranial mass (e.g., glioma, meningioma) that could potentially impair cognition","NA","clinical_exam","must not"
"NCT03443973","exclusion","comorbidities","CNS infection history","history/presence of","NA","NA","NA","NA","NA","Presence of infections that affect brain function or history of infections that resulted in neurologic sequelae","NA","clinical_exam","must not"
"NCT03443973","exclusion","comorbidities","Stroke/TIA history","history/presence of","NA","NA","NA","NA","NA","History or presence of systemic autoimmune disorders that potentially cause progressive neurologic disease with associated cognitive deficits","NA","clinical_exam","must not"
"NCT03443973","exclusion","comorbidities","Stroke/TIA history","history/presence of","NA","NA","NA","NA","NA","History or presence of systemic autoimmune disorders that potentially cause progressive neurologic disease with associated cognitive deficits","NA","clinical_exam","must not"
"NCT03443973","exclusion","other","NA","history/presence of","NA","NA","NA","NA","NA","At risk for suicide in the opinion of the investigator","NA","NA","must not"
"NCT03443973","exclusion","lifestyle","Alcohol/substance use","NA","NA","NA","NA","NA","NA","Alcohol and/or substance abuse or dependants in past 2 years","NA","questionnaire","must not"
"NCT03443973","exclusion","lifestyle","Alcohol/substance use","NA","NA","NA","NA","NA","NA","Alcohol and/or substance abuse or dependants in past 2 years","NA","questionnaire","must not"
"NCT03443973","exclusion","demographics","Age","NA","NA","NA","NA","NA","NA","Alcohol and/or substance abuse or dependants in past 2 years","NA","NA","must not"
"NCT03443973","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Relevant brain hemorrhage, bleeding disorder and cerebrovascular abnormalities","NA","NA","must not"
"NCT03443973","exclusion","imaging","Brain MRI","absent","NA","NA","NA","NA","NA","Any contraindications to brain MRI","NA","MRI","must not"
"NCT03443973","exclusion","safety_labs","Safety labs/organ function","history/presence of","NA","NA","NA","NA","NA","Unstable or clinically significant cardiovascular, kidney or liver disease","NA","lab_test","must not"
"NCT03443973","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Uncontrolled hypertension","NA","NA","must not"
"NCT03443973","exclusion","other","NA","history/presence of","NA","NA","NA","NA","NA","Unstable or clinically significant cardiovascular disease","NA","NA","must not"
"NCT03443973","exclusion","safety_labs","Safety labs/organ function","NA","NA","NA","NA","NA","NA","Abnormal thyroid function","NA","lab_test","must not"
"NCT03443973","exclusion","safety_labs","Safety labs/organ function","NA","NA","NA","NA","NA","NA","Patients with evidence of folic acid deficiency","NA","lab_test","must not"
"NCT03443973","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Discontinued from study treatment during the double-blind treatment period","NA","NA","must not"
"NCT03443973","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Received any other investigational medication during the double-blind treatment period or after the end of double-blind treatment","NA","NA","must not"
"NCT03443973","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Participation in the OLE deemed inappropriate by the investigator","NA","NA","must not"
"NCT03443973","exclusion","imaging","Brain MRI","history/presence of","NA","NA","NA","NA","NA","Presence of ARIA-E findings at the Week 116 MRI scan","NA","MRI","must not"
"NCT03444870","inclusion","other","AD dementia diagnosis","NA","NA","NA","NA","NIA-AA","prodromal AD","Meets National Institute on Aging/Alzheimer's Association (NIAAA) core clinical criteria for probable AD dementia or prodromal AD (consistent with the NIAAA diagnostic criteria and guidelines for mild cognitive impairment)","NA","clinical_exam","must"
"NCT03444870","inclusion","other","MCI diagnosis","NA","NA","NA","NA","NIA-AA","prodromal AD","Meets National Institute on Aging/Alzheimer's Association (NIAAA) core clinical criteria for probable AD dementia or prodromal AD (consistent with the NIAAA diagnostic criteria and guidelines for mild cognitive impairment)","NA","clinical_exam","must"
"NCT03444870","inclusion","other","MCI diagnosis","NA","NA","NA","NA","NIA-AA","prodromal AD","Meets National Institute on Aging/Alzheimer's Association (NIAAA) core clinical criteria for probable AD dementia or prodromal AD (consistent with the NIAAA diagnostic criteria and guidelines for mild cognitive impairment)","NA","clinical_exam","must"
"NCT03444870","inclusion","imaging","Amyloid PET","positive","NA","NA","NA","NA","NA","Evidence of the AD pathological process, as confirmed by CSF tau/A-beta42or amyloid PET scan","NA","PET","must"
"NCT03444870","inclusion","other","NA","NA","NA","NA","NA","NA","NA","Demonstrated abnormal memory function","NA","NA","must"
"NCT03444870","inclusion","cognition","MMSE",">=","22","NA","score","NA","NA","MMSE score greater than or equal to 22 (≥ 22)","NA","cognitive_test","must"
"NCT03444870","inclusion","global_impairment","CDR global score","NA","NA","NA","NA","NA","NA","Clinical dementia rating-global score (CDR-GS) of 0.5 or 1.0","NA","clinical_exam","must"
"NCT03444870","inclusion","global_impairment","CDR global score","NA","NA","NA","NA","NA","NA","Clinical dementia rating-global score (CDR-GS) of 0.5 or 1.0","NA","clinical_exam","must"
"NCT03444870","inclusion","demographics","Age","able/willing","NA","NA","NA","NA","NA","Availability of a reliable study partner who accepts to participate in study procedures throughout the 2 years duration of study","NA","NA","must"
"NCT03444870","inclusion","medications","Concomitant AD medications","NA","NA","NA","NA","NA","NA","If receiving symptomatic AD medications, the dosing regimen must have been stable for 3 months prior to screening and until randomization","prior to screening","NA","must"
"NCT03444870","inclusion","other","NA","NA","NA","NA","NA","NA","NA","For enrollment in the China extension, patients must have residence in mainland China, Hong Kong, or Taiwan and be of Chinese ancestry","NA","NA","must"
"NCT03444870","inclusion","demographics","Sex/pregnancy","NA","NA","NA","NA","NA","NA","For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods","NA","NA","must"
"NCT03444870","inclusion","study_operations","Reproductive/blood donation","NA","NA","NA","NA","NA","NA","For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods","NA","NA","must"
"NCT03444870","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Any evidence of a condition other than AD that may affect cognition","NA","NA","may"
"NCT03444870","exclusion","comorbidities","Psychiatric disorder history","history/presence of","NA","NA","NA","NA","NA","History of schizophrenia, schizoaffective disorder, major depression, or bipolar disorder","NA","clinical_exam","must not"
"NCT03444870","exclusion","comorbidities","Stroke/TIA history","history/presence of","NA","NA","NA","NA","NA","History or presence of clinically evident systemic vascular disease that in the opinion of the investigator has the potential to affect cognitive function","NA","clinical_exam","must not"
"NCT03444870","exclusion","other","NA","history/presence of","NA","NA","NA","NA","NA","History or presence of clinically evident cerebrovascular disease","NA","NA","must not"
"NCT03444870","exclusion","other","NA","history/presence of","NA","NA","NA","NA","NA","History or presence of posterior reversible encephalopathy syndrome","NA","NA","must not"
"NCT03444870","exclusion","safety_labs","Safety labs/organ function","history/presence of","NA","NA","NA","NA","NA","History or presence of any stroke with clinical symptoms within the past 12 months, or documented history within the last 6 months of an acute event that is consistent with a transient ischemic attack","within the past 12 months","lab_test","must not"
"NCT03444870","exclusion","safety_labs","Safety labs/organ function","history/presence of","NA","NA","NA","NA","NA","History or presence of any stroke with clinical symptoms within the past 12 months, or documented history within the last 6 months of an acute event that is consistent with a transient ischemic attack","within the past 12 months","lab_test","must not"
"NCT03444870","exclusion","safety_labs","Safety labs/organ function","history/presence of","NA","NA","NA","NA","NA","History or presence of any stroke with clinical symptoms within the past 12 months, or documented history within the last 6 months of an acute event that is consistent with a transient ischemic attack","within the past 12 months","lab_test","must not"
"NCT03444870","exclusion","other","NA","history/presence of","NA","NA","NA","NA","NA","History of severe, clinically significant CNS trauma","NA","NA","must not"
"NCT03444870","exclusion","comorbidities","Stroke/TIA history","history/presence of","NA","NA","NA","NA","NA","History or presence of intracranial mass (e.g., glioma, meningioma) that could potentially impair cognition","NA","clinical_exam","must not"
"NCT03444870","exclusion","comorbidities","CNS infection history","history/presence of","NA","NA","NA","NA","NA","Presence of infections that affect brain function or history of infections that resulted in neurologic sequelae","NA","clinical_exam","must not"
"NCT03444870","exclusion","comorbidities","Stroke/TIA history","history/presence of","NA","NA","NA","NA","NA","History or presence of systemic autoimmune disorders that potentially cause progressive neurologic disease with associated cognitive deficits","NA","clinical_exam","must not"
"NCT03444870","exclusion","comorbidities","Stroke/TIA history","history/presence of","NA","NA","NA","NA","NA","History or presence of systemic autoimmune disorders that potentially cause progressive neurologic disease with associated cognitive deficits","NA","clinical_exam","must not"
"NCT03444870","exclusion","other","NA","history/presence of","NA","NA","NA","NA","NA","At risk for suicide in the opinion of the investigator","NA","NA","must not"
"NCT03444870","exclusion","lifestyle","Alcohol/substance use","NA","NA","NA","NA","NA","NA","Alcohol and/or substance abuse or dependants in past 2 years","NA","questionnaire","must not"
"NCT03444870","exclusion","lifestyle","Alcohol/substance use","NA","NA","NA","NA","NA","NA","Alcohol and/or substance abuse or dependants in past 2 years","NA","questionnaire","must not"
"NCT03444870","exclusion","demographics","Age","NA","NA","NA","NA","NA","NA","Alcohol and/or substance abuse or dependants in past 2 years","NA","NA","must not"
"NCT03444870","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Relevant brain hemorrhage, bleeding disorder and cerebrovascular abnormalities","NA","NA","must not"
"NCT03444870","exclusion","imaging","Brain MRI","absent","NA","NA","NA","NA","NA","Any contraindications to brain MRI","NA","MRI","must not"
"NCT03444870","exclusion","safety_labs","Safety labs/organ function","history/presence of","NA","NA","NA","NA","NA","Unstable or clinically significant cardiovascular, kidney or liver disease","NA","lab_test","must not"
"NCT03444870","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Uncontrolled hypertension","NA","NA","must not"
"NCT03444870","exclusion","other","NA","history/presence of","NA","NA","NA","NA","NA","Unstable or clinically significant cardiovascular disease","NA","NA","must not"
"NCT03444870","exclusion","safety_labs","Safety labs/organ function","NA","NA","NA","NA","NA","NA","Abnormal thyroid function","NA","lab_test","must not"
"NCT03444870","exclusion","safety_labs","Safety labs/organ function","NA","NA","NA","NA","NA","NA","Patients with evidence of folic acid deficiency","NA","lab_test","must not"
"NCT03444870","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Discontinued from study treatment during the double-blind treatment period","NA","NA","must not"
"NCT03444870","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Received any other investigational medication during the double-blind treatment period or after the end of double-blind treatment","NA","NA","must not"
"NCT03444870","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Participation in the OLE deemed inappropriate by the investigator","NA","NA","must not"
"NCT03444870","exclusion","imaging","Brain MRI","history/presence of","NA","NA","NA","NA","NA","Presence of ARIA-E findings at the Week 116 MRI scan","NA","MRI","must not"
"NCT03887455","inclusion","cognition","Objective cognitive impairment","NA","NA","NA","NA","NA","NA","Objective impairment in episodic memory as indicated by at least 1 standard deviation below age-adjusted mean in the Wechsler Memory Scale IV-Logical Memory (subscale) II (WMS-IV LMII)","NA","cognitive_test","must"
"NCT03887455","inclusion","biomarkers","Amyloid pathology","positive","NA","NA","NA","NA","NA","Positive biomarker for brain amyloid pathology","NA","NA","must"
"NCT03887455","inclusion","demographics","Sex/pregnancy","NA","NA","NA","NA","NA","NA","Male or female participants aged greater than or equal to (\>=) 50 and less than or equal to (\<=) 90 years, at the time of informed consent","NA","NA","must"
"NCT03887455","inclusion","demographics","Age","NA","NA","NA","NA","NA","NA","Male or female participants aged greater than or equal to (\>=) 50 and less than or equal to (\<=) 90 years, at the time of informed consent","NA","NA","must"
"NCT03887455","inclusion","demographics","Age","NA","NA","NA","NA","NA","NA","Male or female participants aged greater than or equal to (\>=) 50 and less than or equal to (\<=) 90 years, at the time of informed consent","NA","NA","must"
"NCT03887455","inclusion","demographics","Age","NA","NA","NA","NA","NA","NA","Male or female participants aged greater than or equal to (\>=) 50 and less than or equal to (\<=) 90 years, at the time of informed consent","NA","NA","must"
"NCT03887455","inclusion","demographics","Age","consent to","NA","NA","NA","NA","NA","Male or female participants aged greater than or equal to (\>=) 50 and less than or equal to (\<=) 90 years, at the time of informed consent","NA","NA","must"
"NCT03887455","inclusion","cognition","MMSE","between","22","30","score","NA","NA","Mini mental state examination (MMSE) score \>=22 at Screening and Baseline and \<=30 at Screening and Baseline","at screening","cognitive_test","must"
"NCT03887455","inclusion","demographics","Body mass index","NA","NA","NA","NA","NA","NA","Body mass index (BMI) greater than (\>)17 and less than (\<) 35 at Screening","at screening","clinical_exam","must"
"NCT03887455","inclusion","demographics","Body mass index","NA","NA","NA","NA","NA","NA","Body mass index (BMI) greater than (\>)17 and less than (\<) 35 at Screening","at screening","clinical_exam","must"
"NCT03887455","inclusion","medications","Concomitant AD medications","NA","NA","NA","NA","NA","NA","If receiving an approved Alzheimer's disease treatment such as acetylcholinesterase inhibitor (AChEIs) or memantine or both for Alzheimer's disease, must be on a stable dose for at least 12 weeks prior to Baseline. Treatment-naive participants for Alzheimer's disease can be entered into the study. Unless otherwise stated, participants must have been on stable doses of all other (that is, non-Alzheimer's disease-related) permitted concomitant medications for at least 4 weeks prior to Baseline. Use of memantine will not be allowed for participants in Japan","prior to baseline","NA","must"
"NCT03887455","inclusion","medications","Concomitant AD medications","NA","NA","NA","NA","NA","NA","If receiving an approved Alzheimer's disease treatment such as acetylcholinesterase inhibitor (AChEIs) or memantine or both for Alzheimer's disease, must be on a stable dose for at least 12 weeks prior to Baseline. Treatment-naive participants for Alzheimer's disease can be entered into the study. Unless otherwise stated, participants must have been on stable doses of all other (that is, non-Alzheimer's disease-related) permitted concomitant medications for at least 4 weeks prior to Baseline. Use of memantine will not be allowed for participants in Japan","prior to baseline","NA","must"
"NCT03887455","inclusion","medications","Concomitant AD medications","NA","NA","NA","NA","NA","NA","If receiving an approved Alzheimer's disease treatment such as acetylcholinesterase inhibitor (AChEIs) or memantine or both for Alzheimer's disease, must be on a stable dose for at least 12 weeks prior to Baseline. Treatment-naive participants for Alzheimer's disease can be entered into the study. Unless otherwise stated, participants must have been on stable doses of all other (that is, non-Alzheimer's disease-related) permitted concomitant medications for at least 4 weeks prior to Baseline. Use of memantine will not be allowed for participants in Japan","prior to baseline","NA","must"
"NCT03887455","inclusion","study_operations","Study partner","able/willing","NA","NA","NA","NA","NA","Have an identified study partner (defined as a person able to support the participant for the duration of the study and who spends at least 8 hours per week with the participant)","for the duration of the study","NA","must"
"NCT03887455","inclusion","safety_labs","Safety labs/organ function","NA","NA","NA","NA","NA","NA","Have an identified study partner (defined as a person able to support the participant for the duration of the study and who spends at least 8 hours per week with the participant)","for the duration of the study","lab_test","must"
"NCT03887455","inclusion","study_operations","Informed consent","consent to","NA","NA","NA","NA","NA","Provide written informed consent. If a participant lacks capacity to consent in the investigator's opinion, the participant's assent should be obtained, if required in accordance with local laws, regulations and customs, plus the written informed consent of a legal representative should be obtained (capacity to consent and definition of legal representative should be determined in accordance with applicable local laws and regulations). In countries where local laws, regulations, and customs do not permit participants who lack capacity to consent to participate in this study (example, Germany and Spain), they will not be enrolled","NA","NA","should"
"NCT03887455","inclusion","other","NA","NA","NA","NA","NA","NA","NA","Participants who have completed the Core Study (except de novo participants)","NA","NA","must"
"NCT03887455","inclusion","study_operations","Study partner","able/willing","NA","NA","NA","NA","NA","Must continue to have a study partner who is willing and able to provide follow-up information on the participant throughout the course of the Extension Phase","NA","NA","must"
"NCT03887455","inclusion","study_operations","Informed consent","consent to","NA","NA","NA","NA","NA","Provide written informed consent for the Extension Phase. If a participant lacks capacity to consent in the investigator's opinion, the participant's assent should be obtained, if required and in accordance with local laws, regulations and customs, plus the written informed consent of a legal representative should be obtained (capacity to consent and definition of legal representative should be determined in accordance with applicable local laws and regulations). In countries where local laws, regulations, and customs do not permit participants who lack capacity to consent to participate in this study (example, Germany and Spain), they will not be enrolled","NA","NA","should"
"NCT03887455","inclusion","imaging","Amyloid PET","able/willing","NA","NA","NA","NA","NA","Participants entering the subcutaneous (vial) substudy at Extension Phase Week 1, must be willing to participate, or continue participating in the amyloid positron emission tomography (PET) substudy. All participants must have an amyloid PET scan within 4 weeks before starting subcutaneous BAN2401","NA","PET","must"
"NCT03887455","inclusion","imaging","Amyloid PET","NA","NA","NA","NA","NA","NA","Participants entering the subcutaneous (vial) substudy at Extension Phase Week 1, must be willing to participate, or continue participating in the amyloid positron emission tomography (PET) substudy. All participants must have an amyloid PET scan within 4 weeks before starting subcutaneous BAN2401","NA","PET","must"
"NCT03887455","inclusion","safety_labs","Safety labs/organ function","NA","NA","NA","NA","NA","NA","Participants enrolling into the subcutaneous autoinjector substudy must have had at least 6 months exposure to BAN2401 10 mg/kg intravenously biweekly or BAN2401 Dose 1 subcutaneously weekly.","NA","lab_test","must"
"NCT03887455","inclusion","other","NA","NA","NA","NA","NA","NA","NA","Participants enrolling into the subcutaneous Dose 3 autoinjector substudy must have previously received BAN2401 by either intravenous administration and/or subcutaneous autoinjector administration and must have completed Visit 82 (Extension Week 79) at a minimum, regardless of previous route of administration","NA","NA","must"
"NCT03887455","inclusion","other","NA","NA","NA","NA","NA","NA","NA","Participants enrolling into the subcutaneous Dose 3 autoinjector substudy must have previously received BAN2401 by either intravenous administration and/or subcutaneous autoinjector administration and must have completed Visit 82 (Extension Week 79) at a minimum, regardless of previous route of administration","NA","NA","must"
"NCT03887455","inclusion","other","NA","NA","NA","NA","NA","NA","NA","Must have completed Week 207 in the Extension Phase","NA","NA","must"
"NCT03887455","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Any neurological condition that may be contributing to cognitive impairment above and beyond that caused by the participant's Alzheimer's disease","NA","NA","may"
"NCT03887455","exclusion","comorbidities","Stroke/TIA history","history/presence of","NA","NA","NA","NA","NA","History of transient ischemic attacks (TIA), stroke, or seizures within 12 months of Screening","NA","clinical_exam","must not"
"NCT03887455","exclusion","comorbidities","Seizure history","NA","NA","NA","NA","NA","NA","History of transient ischemic attacks (TIA), stroke, or seizures within 12 months of Screening","NA","clinical_exam","must not"
"NCT03887455","exclusion","comorbidities","Psychiatric disorder history","history/presence of","NA","NA","NA","NA","NA","Any psychiatric diagnosis or symptoms (example, hallucinations, major depression, or delusions) that could interfere with study procedures in the participant","NA","clinical_exam","must not"
"NCT03887455","exclusion","comorbidities","Geriatric Depression Scale",">=","8","NA","score","NA","NA","Geriatric Depression Scale (GDS) score \>=8 at Screening","at screening","questionnaire","must not"
"NCT03887455","exclusion","imaging","Brain MRI","absent","NA","NA","NA","NA","NA","Contraindications to MRI scanning, including cardiac pacemaker/defibrillator, ferromagnetic metal implants (example in skull and cardiac devices other than those approved as safe for use in MRI scanners)","NA","MRI","must not"
"NCT03887455","exclusion","imaging","Brain MRI","history/presence of","NA","NA","NA","NA","NA","Evidence of other clinically significant lesions on brain MRI at Screening that could indicate a dementia diagnosis other than Alzheimer's disease","at screening","MRI","must not"
"NCT03887455","exclusion","imaging","Brain MRI","NA","NA","NA","NA","NA","NA","Other significant pathological findings on brain MRI at screening, including but not limited to: more than 4 microhemorrhages (defined as 10 millimeter \[mm\] or less at the greatest diameter); a single macrohemorrhage \>10 mm at greatest diameter; an area of superficial siderosis; evidence of vasogenic edema; evidence of cerebral contusion, encephalomalacia, aneurysms, vascular malformations, or infective lesions; evidence of multiple lacunar infarcts or stroke involving a major vascular territory, severe small vessel, or white matter disease; space occupying lesions; or brain tumors (however, lesions diagnosed as meningiomas or arachnoid cysts and \<1 centimeter \[cm\] at their greatest diameter need not be exclusionary)","at screening","MRI","must not"
"NCT03887455","exclusion","imaging","Brain MRI",">","10","NA","mm","NA","NA","Other significant pathological findings on brain MRI at screening, including but not limited to: more than 4 microhemorrhages (defined as 10 millimeter \[mm\] or less at the greatest diameter); a single macrohemorrhage \>10 mm at greatest diameter; an area of superficial siderosis; evidence of vasogenic edema; evidence of cerebral contusion, encephalomalacia, aneurysms, vascular malformations, or infective lesions; evidence of multiple lacunar infarcts or stroke involving a major vascular territory, severe small vessel, or white matter disease; space occupying lesions; or brain tumors (however, lesions diagnosed as meningiomas or arachnoid cysts and \<1 centimeter \[cm\] at their greatest diameter need not be exclusionary)","at screening","MRI","must not"
"NCT03887455","exclusion","imaging","Brain MRI","NA","NA","NA","NA","NA","NA","Other significant pathological findings on brain MRI at screening, including but not limited to: more than 4 microhemorrhages (defined as 10 millimeter \[mm\] or less at the greatest diameter); a single macrohemorrhage \>10 mm at greatest diameter; an area of superficial siderosis; evidence of vasogenic edema; evidence of cerebral contusion, encephalomalacia, aneurysms, vascular malformations, or infective lesions; evidence of multiple lacunar infarcts or stroke involving a major vascular territory, severe small vessel, or white matter disease; space occupying lesions; or brain tumors (however, lesions diagnosed as meningiomas or arachnoid cysts and \<1 centimeter \[cm\] at their greatest diameter need not be exclusionary)","at screening","MRI","must not"
"NCT03887455","exclusion","comorbidities","Stroke/TIA history","NA","NA","NA","NA","NA","NA","Other significant pathological findings on brain MRI at screening, including but not limited to: more than 4 microhemorrhages (defined as 10 millimeter \[mm\] or less at the greatest diameter); a single macrohemorrhage \>10 mm at greatest diameter; an area of superficial siderosis; evidence of vasogenic edema; evidence of cerebral contusion, encephalomalacia, aneurysms, vascular malformations, or infective lesions; evidence of multiple lacunar infarcts or stroke involving a major vascular territory, severe small vessel, or white matter disease; space occupying lesions; or brain tumors (however, lesions diagnosed as meningiomas or arachnoid cysts and \<1 centimeter \[cm\] at their greatest diameter need not be exclusionary)","at screening","clinical_exam","must not"
"NCT03887455","exclusion","imaging","Brain MRI","NA","NA","NA","NA","NA","NA","Other significant pathological findings on brain MRI at screening, including but not limited to: more than 4 microhemorrhages (defined as 10 millimeter \[mm\] or less at the greatest diameter); a single macrohemorrhage \>10 mm at greatest diameter; an area of superficial siderosis; evidence of vasogenic edema; evidence of cerebral contusion, encephalomalacia, aneurysms, vascular malformations, or infective lesions; evidence of multiple lacunar infarcts or stroke involving a major vascular territory, severe small vessel, or white matter disease; space occupying lesions; or brain tumors (however, lesions diagnosed as meningiomas or arachnoid cysts and \<1 centimeter \[cm\] at their greatest diameter need not be exclusionary)","at screening","MRI","must not"
"NCT03887455","exclusion","comorbidities","Malignancy","NA","NA","NA","NA","NA","NA","Other significant pathological findings on brain MRI at screening, including but not limited to: more than 4 microhemorrhages (defined as 10 millimeter \[mm\] or less at the greatest diameter); a single macrohemorrhage \>10 mm at greatest diameter; an area of superficial siderosis; evidence of vasogenic edema; evidence of cerebral contusion, encephalomalacia, aneurysms, vascular malformations, or infective lesions; evidence of multiple lacunar infarcts or stroke involving a major vascular territory, severe small vessel, or white matter disease; space occupying lesions; or brain tumors (however, lesions diagnosed as meningiomas or arachnoid cysts and \<1 centimeter \[cm\] at their greatest diameter need not be exclusionary)","at screening","clinical_exam","must not"
"NCT03887455","exclusion","imaging","Brain MRI","NA","NA","NA","NA","NA","NA","Other significant pathological findings on brain MRI at screening, including but not limited to: more than 4 microhemorrhages (defined as 10 millimeter \[mm\] or less at the greatest diameter); a single macrohemorrhage \>10 mm at greatest diameter; an area of superficial siderosis; evidence of vasogenic edema; evidence of cerebral contusion, encephalomalacia, aneurysms, vascular malformations, or infective lesions; evidence of multiple lacunar infarcts or stroke involving a major vascular territory, severe small vessel, or white matter disease; space occupying lesions; or brain tumors (however, lesions diagnosed as meningiomas or arachnoid cysts and \<1 centimeter \[cm\] at their greatest diameter need not be exclusionary)","at screening","MRI","must not"
"NCT03887455","exclusion","imaging","Brain MRI","<","NA","1","cm","NA","NA","Other significant pathological findings on brain MRI at screening, including but not limited to: more than 4 microhemorrhages (defined as 10 millimeter \[mm\] or less at the greatest diameter); a single macrohemorrhage \>10 mm at greatest diameter; an area of superficial siderosis; evidence of vasogenic edema; evidence of cerebral contusion, encephalomalacia, aneurysms, vascular malformations, or infective lesions; evidence of multiple lacunar infarcts or stroke involving a major vascular territory, severe small vessel, or white matter disease; space occupying lesions; or brain tumors (however, lesions diagnosed as meningiomas or arachnoid cysts and \<1 centimeter \[cm\] at their greatest diameter need not be exclusionary)","at screening","MRI","must not"
"NCT03887455","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Any immunological disease which is not adequately controlled, or which requires treatment with immunoglobulins, systemic monoclonal antibodies (or derivatives of monoclonal antibodies), systemic immunosuppressants, or plasmapheresis during the study","NA","NA","must not"
"NCT03887455","exclusion","safety_labs","Safety labs/organ function","<","NA","50","NA","NA","NA","Participants with a bleeding disorder that is not under adequate control (including a platelet count \<50,000 or international normalized ratio \[INR\] \>1.5 for participants who are not on anticoagulant treatment, example, warfarin). Participants who are on anticoagulant therapy should have their anticoagulant status optimized and be on a stable dose for 4 weeks before Screening. Participants who are on anticoagulant therapy are not permitted to participate in cerebrospinal fluid (CSF) assessments","NA","lab_test","should"
"NCT03887455","exclusion","medications","Anticoagulant/antiplatelet use",">","1.5","NA","NA","NA","NA","Participants with a bleeding disorder that is not under adequate control (including a platelet count \<50,000 or international normalized ratio \[INR\] \>1.5 for participants who are not on anticoagulant treatment, example, warfarin). Participants who are on anticoagulant therapy should have their anticoagulant status optimized and be on a stable dose for 4 weeks before Screening. Participants who are on anticoagulant therapy are not permitted to participate in cerebrospinal fluid (CSF) assessments","NA","CSF","should"
"NCT03887455","exclusion","biomarkers","CSF biomarkers","NA","NA","NA","NA","NA","NA","Participants with a bleeding disorder that is not under adequate control (including a platelet count \<50,000 or international normalized ratio \[INR\] \>1.5 for participants who are not on anticoagulant treatment, example, warfarin). Participants who are on anticoagulant therapy should have their anticoagulant status optimized and be on a stable dose for 4 weeks before Screening. Participants who are on anticoagulant therapy are not permitted to participate in cerebrospinal fluid (CSF) assessments","NA","CSF","should"
"NCT03887455","exclusion","safety_labs","Safety labs/organ function","NA","NA","NA","NA","NA","NA","Any other medical conditions (example, cardiac, respiratory, gastrointestinal, renal disease) which are not stably and adequately controlled, or which in the opinion of the investigator(s) could affect the participant's safety or interfere with the study assessments","NA","lab_test","must not"
"NCT03887455","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Participation in a clinical study involving any therapeutic monoclonal antibody, protein derived from a monoclonal antibody, immunoglobulin therapy, or vaccine within 6 months before screening unless it can be documented that the participant was randomized to placebo","NA","NA","must not"
"NCT03887455","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Participation in a clinical study involving any anti-amyloid therapies (including any monoclonal antibody therapies and any β-site amyloid precursor protein cleaving enzyme \[BACE\] inhibitor therapies) unless it can be documented that the participant only received placebo","NA","NA","must not"
"NCT03887455","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Participants who have any known prior exposure to lecanemab","NA","NA","must not"
"NCT03887455","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Participants who were dosed in a clinical study involving any new chemical entities for AD within 6 months prior to screening unless it can be documented that the participant was in a placebo treatment arm","prior to screening","NA","must not"
"NCT03887455","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Extension Phase: Exclusion Criteria","NA","NA","must not"
"NCT03887455","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Participants who discontinued early from the Core Study","NA","NA","must not"
"NCT03887455","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Participants who develop the following conditions from the time of Screening for the Core Study to the start of the Extension Phase","NA","NA","must not"
"NCT03887455","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Any neurological condition that may be contributing to cognitive impairment above and beyond that caused by the participant's AD","NA","NA","may"
"NCT03887455","exclusion","comorbidities","Psychiatric disorder history","history/presence of","NA","NA","NA","NA","NA","Any psychiatric diagnosis or symptoms, (example, hallucinations, major depression, or delusions) that could interfere with study procedures in the participant","NA","clinical_exam","must not"
"NCT03887455","exclusion","imaging","Brain MRI","absent","NA","NA","NA","NA","NA","Contraindications to MRI scanning, including cardiac pacemaker/defibrillator, ferromagnetic metal implants (example, in skull and cardiac devices other than those approved as safe for use in MRI scanners)","NA","MRI","must not"
"NCT03887455","exclusion","imaging","Brain MRI","NA","NA","NA","NA","NA","NA","Other significant pathological findings on brain MRI during the Core Study including but not limited to: cerebral contusion, encephalomalacia, aneurysms, vascular malformations, or infective lesions; evidence of multiple lacunar infarcts or stroke involving a major vascular territory, severe small vessel, or white matter disease; space occupying lesions; or brain tumors will be exclusionary if based on the opinion of the investigator, with consultation of medical monitor, these findings may interfere with the study procedures or safety","NA","MRI","may"
"NCT03887455","exclusion","imaging","Brain MRI","NA","NA","NA","NA","NA","NA","Other significant pathological findings on brain MRI during the Core Study including but not limited to: cerebral contusion, encephalomalacia, aneurysms, vascular malformations, or infective lesions; evidence of multiple lacunar infarcts or stroke involving a major vascular territory, severe small vessel, or white matter disease; space occupying lesions; or brain tumors will be exclusionary if based on the opinion of the investigator, with consultation of medical monitor, these findings may interfere with the study procedures or safety","NA","MRI","may"
"NCT03887455","exclusion","comorbidities","Stroke/TIA history","NA","NA","NA","NA","NA","NA","Other significant pathological findings on brain MRI during the Core Study including but not limited to: cerebral contusion, encephalomalacia, aneurysms, vascular malformations, or infective lesions; evidence of multiple lacunar infarcts or stroke involving a major vascular territory, severe small vessel, or white matter disease; space occupying lesions; or brain tumors will be exclusionary if based on the opinion of the investigator, with consultation of medical monitor, these findings may interfere with the study procedures or safety","NA","clinical_exam","may"
"NCT03887455","exclusion","imaging","Brain MRI","NA","NA","NA","NA","NA","NA","Other significant pathological findings on brain MRI during the Core Study including but not limited to: cerebral contusion, encephalomalacia, aneurysms, vascular malformations, or infective lesions; evidence of multiple lacunar infarcts or stroke involving a major vascular territory, severe small vessel, or white matter disease; space occupying lesions; or brain tumors will be exclusionary if based on the opinion of the investigator, with consultation of medical monitor, these findings may interfere with the study procedures or safety","NA","MRI","may"
"NCT03887455","exclusion","comorbidities","Malignancy","NA","NA","NA","NA","NA","NA","Other significant pathological findings on brain MRI during the Core Study including but not limited to: cerebral contusion, encephalomalacia, aneurysms, vascular malformations, or infective lesions; evidence of multiple lacunar infarcts or stroke involving a major vascular territory, severe small vessel, or white matter disease; space occupying lesions; or brain tumors will be exclusionary if based on the opinion of the investigator, with consultation of medical monitor, these findings may interfere with the study procedures or safety","NA","clinical_exam","may"
"NCT03887455","exclusion","imaging","Brain MRI","NA","NA","NA","NA","NA","NA","Other significant pathological findings on brain MRI during the Core Study including but not limited to: cerebral contusion, encephalomalacia, aneurysms, vascular malformations, or infective lesions; evidence of multiple lacunar infarcts or stroke involving a major vascular territory, severe small vessel, or white matter disease; space occupying lesions; or brain tumors will be exclusionary if based on the opinion of the investigator, with consultation of medical monitor, these findings may interfere with the study procedures or safety","NA","MRI","may"
"NCT03887455","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Hypersensitivity to BAN2401 or any of the excipients, or to any monoclonal antibody treatment","NA","NA","must not"
"NCT03887455","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Any immunological disease which is not adequately controlled, or which requires chronic treatment with immunoglobulins, systemic monoclonal antibodies (or derivatives of monoclonal antibodies), systemic immunosuppressants, or plasmapheresis during the study","NA","NA","must not"
"NCT03887455","exclusion","other","NA","history/presence of","NA","NA","NA","NA","NA","Any other clinically significant abnormalities in physical examination, vital signs, laboratory tests, or ECG, which in the opinion of the investigator require further investigation or treatment or which may interfere with study procedures or safety","NA","NA","may"
"NCT03887455","exclusion","comorbidities","Malignancy","NA","NA","NA","NA","NA","NA","Malignant neoplasms (except for basal or squamous cell carcinoma in situ of the skin, or localized prostate cancer in male participants) that are not stably and adequately controlled or which, based on the opinion of the investigator, may interfere with the participant's safety or participation in the study","NA","clinical_exam","may"
"NCT03887455","exclusion","demographics","Sex/pregnancy","NA","NA","NA","NA","NA","NA","Malignant neoplasms (except for basal or squamous cell carcinoma in situ of the skin, or localized prostate cancer in male participants) that are not stably and adequately controlled or which, based on the opinion of the investigator, may interfere with the participant's safety or participation in the study","NA","NA","may"
"NCT03887455","exclusion","demographics","Sex/pregnancy","NA","NA","NA","NA","NA","NA","Malignant neoplasms (except for basal or squamous cell carcinoma in situ of the skin, or localized prostate cancer in male participants) that are not stably and adequately controlled or which, based on the opinion of the investigator, may interfere with the participant's safety or participation in the study","NA","NA","may"
"NCT03887455","exclusion","demographics","Sex/pregnancy","NA","NA","NA","NA","NA","NA","Malignant neoplasms (except for basal or squamous cell carcinoma in situ of the skin, or localized prostate cancer in male participants) that are not stably and adequately controlled or which, based on the opinion of the investigator, may interfere with the participant's safety or participation in the study","NA","NA","may"
"NCT03887455","exclusion","safety_labs","Safety labs/organ function","NA","NA","NA","NA","NA","NA","Any other medical conditions (example, cardiac, respiratory, gastrointestinal, renal disease) which are not stably and adequately controlled, or which in the opinion of the investigator(s) could affect the participant's safety or interfere with the study assessments","NA","lab_test","must not"
"NCT03887455","exclusion","comorbidities","Psychiatric disorder history","NA","NA","NA","NA","NA","NA","Severe visual or hearing impairment that would prevent the participant from performing psychometric tests accurately","NA","clinical_exam","must not"
"NCT04437511","inclusion","study_operations","Study partner","NA","NA","NA","NA","NA","NA","Gradual and progressive change in memory function reported by participants or informants for ≥ 6 months","NA","NA","must"
"NCT04437511","inclusion","study_operations","Study partner",">=","6","NA","months","NA","NA","Gradual and progressive change in memory function reported by participants or informants for ≥ 6 months","NA","NA","must"
"NCT04437511","inclusion","cognition","MMSE","between","20","28","score","NA","NA","MMSE score of 20 to 28 (inclusive) at baseline","at baseline","cognitive_test","must"
"NCT04437511","inclusion","imaging","PET imaging","NA","NA","NA","NA","NA","NA","Meet 18F flortaucipir PET scan (central read) criteria - does not apply to safety cohort","NA","PET","must"
"NCT04437511","inclusion","imaging","PET imaging","NA","NA","NA","NA","NA","NA","Meet 18F florbetapir PET scan (central read) criteria","NA","PET","must"
"NCT04437511","inclusion","study_operations","Study partner","consent to","NA","NA","NA","NA","NA","Have a study partner who will provide written informed consent to participate","NA","NA","must"
"NCT04437511","exclusion","imaging","Brain MRI","absent","NA","NA","NA","NA","NA","Contraindication to MRI or PET scans","NA","MRI","must not"
"NCT04437511","exclusion","imaging","PET imaging","NA","NA","NA","NA","NA","NA","Contraindication to MRI or PET scans","NA","PET","must not"
"NCT04437511","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Current treatment with immunoglobulin G (IgG) therapy","NA","NA","must not"
"NCT04592341","inclusion","other","AD dementia diagnosis","NA","NA","NA","NA","NA","prodromal AD","Probable Alzheimer's Disease (AD) dementia or prodromal AD.","NA","clinical_exam","must"
"NCT04592341","inclusion","other","AD dementia diagnosis","NA","NA","NA","NA","NA","prodromal AD","Probable Alzheimer's Disease (AD) dementia or prodromal AD.","NA","clinical_exam","must"
"NCT04592341","inclusion","study_operations","Study partner","able/willing","NA","NA","NA","NA","NA","Availability of a reliable study partner (non-professional caregiver) who accepts to participate in study procedure throughout the study duration","NA","NA","must"
"NCT04592341","inclusion","imaging","Brain MRI","able/willing","NA","NA","NA","NA","NA","The participant should be capable of completing all aspects of study assessments including MRI, clinical genotyping, and PET imaging, either alone or with the help of the study partner (non-professional caregiver).","NA","MRI","should"
"NCT04592341","inclusion","imaging","PET imaging","NA","NA","NA","NA","NA","NA","The participant should be capable of completing all aspects of study assessments including MRI, clinical genotyping, and PET imaging, either alone or with the help of the study partner (non-professional caregiver).","NA","PET","should"
"NCT04592341","inclusion","study_operations","Study partner","NA","NA","NA","NA","NA","NA","The participant should be capable of completing all aspects of study assessments including MRI, clinical genotyping, and PET imaging, either alone or with the help of the study partner (non-professional caregiver).","NA","PET","should"
"NCT04592341","inclusion","comorbidities","Psychiatric disorder history","NA","NA","NA","NA","NA","NA","Adequate visual and auditory acuitysufficient to perform the neuropsychological testing (eye glasses and hearing aids are permitted).","NA","clinical_exam","must"
"NCT04592341","inclusion","imaging","Amyloid PET","positive","NA","NA","NA","NA","NA","Evidence of AD pathological process, as confirmed by amyloid PET scan by qualitative read by the core/central PET laboratory.","NA","PET","must"
"NCT04592341","inclusion","cognition","MMSE","NA","NA","NA","NA","NA","prodromal AD","Prodromal or mild symptomatology, as defined by a screening Mini-Mental State Examination (MMSE) score \>/=22 and Clinical Dementia Rating global score (CDR-GS) of 0.5 or 1.0, as well as a clinical dementia rating (CDR) memory domain score \>/=0.5.","NA","cognitive_test","must"
"NCT04592341","inclusion","global_impairment","CDR global score","NA","NA","NA","NA","NA","prodromal AD","Prodromal or mild symptomatology, as defined by a screening Mini-Mental State Examination (MMSE) score \>/=22 and Clinical Dementia Rating global score (CDR-GS) of 0.5 or 1.0, as well as a clinical dementia rating (CDR) memory domain score \>/=0.5.","NA","clinical_exam","must"
"NCT04592341","inclusion","cognition","MMSE","NA","NA","NA","NA","NA","prodromal AD","Prodromal or mild symptomatology, as defined by a screening Mini-Mental State Examination (MMSE) score \>/=22 and Clinical Dementia Rating global score (CDR-GS) of 0.5 or 1.0, as well as a clinical dementia rating (CDR) memory domain score \>/=0.5.","NA","cognitive_test","must"
"NCT04592341","inclusion","comorbidities","Stroke/TIA history","NA","NA","NA","NA","NA","prodromal AD","Prodromal or mild symptomatology, as defined by a screening Mini-Mental State Examination (MMSE) score \>/=22 and Clinical Dementia Rating global score (CDR-GS) of 0.5 or 1.0, as well as a clinical dementia rating (CDR) memory domain score \>/=0.5.","NA","clinical_exam","must"
"NCT04592341","inclusion","medications","Concomitant AD medications","NA","NA","NA","NA","NA","NA","If the participant is receiving symptomatic AD medications, a stable dosing regimen for at least 3 months prior to screening and until start of study treatment.","prior to screening","NA","must"
"NCT04592341","inclusion","medications","Concomitant AD medications","NA","NA","NA","NA","NA","NA","If the participant is receiving symptomatic AD medications, a stable dosing regimen for at least 3 months prior to screening and until start of study treatment.","prior to screening","NA","must"
"NCT04592341","inclusion","study_operations","Reproductive/blood donation","agree not to","NA","NA","NA","NA","NA","Agreement not to donate blood or blood products for transfusion for the duration of the study and for 1 year after final dose of study drug.","for the duration of the study","NA","must"
"NCT04592341","inclusion","demographics","Age","NA","NA","NA","NA","NA","NA","Agreement not to donate blood or blood products for transfusion for the duration of the study and for 1 year after final dose of study drug.","for the duration of the study","NA","must"
"NCT04592341","inclusion","other","NA","agree not to","NA","NA","NA","NA","NA","Agreement not to participate in other research studies for the duration of this trial, unless these are related Roche-sponsored non-interventional studies.","NA","NA","must"
"NCT04592341","inclusion","demographics","Sex/pregnancy","NA","NA","NA","NA","NA","NA","For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods hat result in a failure rate of \< 1% per year during the treatment period and for at least 16 weeks after the final dose of study drug.","NA","NA","must"
"NCT04592341","inclusion","demographics","Age","<","NA","1","years","NA","NA","For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods hat result in a failure rate of \< 1% per year during the treatment period and for at least 16 weeks after the final dose of study drug.","NA","NA","must"
"NCT04592341","inclusion","safety_labs","Safety labs/organ function","NA","NA","NA","NA","NA","NA","For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods hat result in a failure rate of \< 1% per year during the treatment period and for at least 16 weeks after the final dose of study drug.","NA","lab_test","must"
"NCT04592341","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Any evidence of a condition other than AD that may affect cognition.","NA","NA","may"
"NCT04592341","exclusion","comorbidities","Stroke/TIA history","history/presence of","NA","NA","NA","NA","NA","History or presence of clinically evident systemic vascular disease that in the opinion of the investigator has the potential to affect cognitive function.","NA","clinical_exam","must not"
"NCT04592341","exclusion","other","NA","history/presence of","NA","NA","NA","NA","NA","History or presence of clinically evident cerebrovascular disease.","NA","NA","must not"
"NCT04592341","exclusion","other","NA","history/presence of","NA","NA","NA","NA","NA","History or presence of posterior reversible encephalopathy syndrome.","NA","NA","must not"
"NCT04592341","exclusion","safety_labs","Safety labs/organ function","history/presence of","NA","NA","NA","NA","NA","History or presence of any stroke with clinical symptoms within the past 12 months, or documented history within the last 6 months of an acute event that is consistent with a transient ischemic attack.","within the past 12 months","lab_test","must not"
"NCT04592341","exclusion","safety_labs","Safety labs/organ function","history/presence of","NA","NA","NA","NA","NA","History or presence of any stroke with clinical symptoms within the past 12 months, or documented history within the last 6 months of an acute event that is consistent with a transient ischemic attack.","within the past 12 months","lab_test","must not"
"NCT04592341","exclusion","safety_labs","Safety labs/organ function","history/presence of","NA","NA","NA","NA","NA","History or presence of any stroke with clinical symptoms within the past 12 months, or documented history within the last 6 months of an acute event that is consistent with a transient ischemic attack.","within the past 12 months","lab_test","must not"
"NCT04592341","exclusion","other","NA","history/presence of","NA","NA","NA","NA","NA","History of severe, clinically significant CNS trauma.","NA","NA","must not"
"NCT04592341","exclusion","comorbidities","Stroke/TIA history","history/presence of","NA","NA","NA","NA","NA","History or presence of intracranial mass that could potentially impair cognition.","NA","clinical_exam","must not"
"NCT04592341","exclusion","comorbidities","CNS infection history","history/presence of","NA","NA","NA","NA","NA","Presence of infections that affect brain function or history of infections that resulted in neurologic sequelae.","NA","clinical_exam","must not"
"NCT04592341","exclusion","comorbidities","Stroke/TIA history","history/presence of","NA","NA","NA","NA","NA","History or presence of systemic autoimmune disorders that potentially cause progressive neurologic disease with associated cognitive deficits.","NA","clinical_exam","must not"
"NCT04592341","exclusion","comorbidities","Stroke/TIA history","history/presence of","NA","NA","NA","NA","NA","History or presence of systemic autoimmune disorders that potentially cause progressive neurologic disease with associated cognitive deficits.","NA","clinical_exam","must not"
"NCT04592341","exclusion","comorbidities","Psychiatric disorder history","history/presence of","NA","NA","NA","NA","NA","History of schizophrenia, schizoaffective disorder, major depression, or bipolar disorder.","NA","clinical_exam","must not"
"NCT04592341","exclusion","other","NA","history/presence of","NA","NA","NA","NA","NA","At risk for suicide in the opinion of the investigator.","NA","NA","must not"
"NCT04592341","exclusion","lifestyle","Alcohol/substance use","NA","NA","NA","NA","NA","NA","Alcohol and/or substance abuse or dependants in past 2 years.","NA","questionnaire","must not"
"NCT04592341","exclusion","lifestyle","Alcohol/substance use","NA","NA","NA","NA","NA","NA","Alcohol and/or substance abuse or dependants in past 2 years.","NA","questionnaire","must not"
"NCT04592341","exclusion","demographics","Age","NA","NA","NA","NA","NA","NA","Alcohol and/or substance abuse or dependants in past 2 years.","NA","NA","must not"
"NCT04619420","inclusion","global_impairment","CDR global score","NA","NA","NA","NA","NA","early AD","Early Alzheimer's disease (AD): Gradual and progressive subjective decline in the participant's cognition over at least the past 6 months, as reported by the participant and informant (study partner) and Clinical Dementia Rating-Global Score (CDR-GS) of 0.5 and memory box score greater than or equal to (\>=) 0.5 at screening","at screening","clinical_exam","must"
"NCT04619420","inclusion","safety_labs","Safety labs/organ function","NA","NA","NA","NA","NA","early AD","Early Alzheimer's disease (AD): Gradual and progressive subjective decline in the participant's cognition over at least the past 6 months, as reported by the participant and informant (study partner) and Clinical Dementia Rating-Global Score (CDR-GS) of 0.5 and memory box score greater than or equal to (\>=) 0.5 at screening","at screening","lab_test","must"
"NCT04619420","inclusion","study_operations","Study partner","NA","NA","NA","NA","NA","early AD","Early Alzheimer's disease (AD): Gradual and progressive subjective decline in the participant's cognition over at least the past 6 months, as reported by the participant and informant (study partner) and Clinical Dementia Rating-Global Score (CDR-GS) of 0.5 and memory box score greater than or equal to (\>=) 0.5 at screening","at screening","clinical_exam","must"
"NCT04619420","inclusion","global_impairment","CDR global score","NA","NA","NA","NA","NA","early AD","Early Alzheimer's disease (AD): Gradual and progressive subjective decline in the participant's cognition over at least the past 6 months, as reported by the participant and informant (study partner) and Clinical Dementia Rating-Global Score (CDR-GS) of 0.5 and memory box score greater than or equal to (\>=) 0.5 at screening","at screening","clinical_exam","must"
"NCT04619420","inclusion","global_impairment","CDR Memory Box score","NA","NA","NA","NA","NA","early AD","Early Alzheimer's disease (AD): Gradual and progressive subjective decline in the participant's cognition over at least the past 6 months, as reported by the participant and informant (study partner) and Clinical Dementia Rating-Global Score (CDR-GS) of 0.5 and memory box score greater than or equal to (\>=) 0.5 at screening","at screening","clinical_exam","must"
"NCT04619420","inclusion","imaging","Tau PET","positive","NA","NA","NA","NA","NA","Participants must have positive tau PET results","NA","PET","must"
"NCT04619420","inclusion","demographics","Age","able/willing","NA","NA","NA","NA","NA","Able to read and write and with a minimum 5 years of formal education as reported by participant and study partner at screening","at screening","NA","must"
"NCT04619420","inclusion","demographics","Age","NA","NA","NA","NA","NA","NA","Able to read and write and with a minimum 5 years of formal education as reported by participant and study partner at screening","at screening","NA","must"
"NCT04619420","inclusion","demographics","Age","NA","NA","NA","NA","NA","NA","Able to read and write and with a minimum 5 years of formal education as reported by participant and study partner at screening","at screening","NA","must"
"NCT04619420","inclusion","study_operations","Study partner","NA","NA","NA","NA","NA","NA","Able to read and write and with a minimum 5 years of formal education as reported by participant and study partner at screening","at screening","NA","must"
"NCT04619420","inclusion","study_operations","Study partner","NA","NA","NA","NA","NA","NA","Have a designated study partner who has adequate literacy to participate and be judged to have high likelihood of completing the study with the participant","NA","NA","must"
"NCT04619420","inclusion","demographics","Sex/pregnancy","agree not to","NA","NA","NA","NA","NA","Male participants must agree not to donate sperm for the purpose of reproduction during the study and up to 16 weeks after receiving the last dose of study intervention","NA","NA","must"
"NCT04619420","inclusion","safety_labs","Safety labs/organ function","NA","NA","NA","NA","NA","NA","Male participants must agree not to donate sperm for the purpose of reproduction during the study and up to 16 weeks after receiving the last dose of study intervention","NA","lab_test","must"
"NCT04619420","exclusion","comorbidities","Stroke/TIA history",">=","2","NA","score","NA","NA","Participants with CDR GS \>=2 at predose baseline Clinical Dementia Rating (CDR) administration","NA","clinical_exam","must not"
"NCT04619420","exclusion","other","MCI diagnosis","NA","NA","NA","NA","NA","NA","Participants who fulfill diagnostic criteria for Mild Cognitive Impairment (MCI) or dementia/mild or major neurocognitive disorder suspected to be due to any etiology other than AD (example, Parkinson's disease, cerebrovascular disease, normal pressure hydrocephalus, head injury, drug or alcohol abuse/dependence, anoxic brain injury, (Et cetera\[etc\])","NA","clinical_exam","must not"
"NCT04619420","exclusion","comorbidities","Stroke/TIA history","NA","NA","NA","NA","NA","NA","Participants who fulfill diagnostic criteria for Mild Cognitive Impairment (MCI) or dementia/mild or major neurocognitive disorder suspected to be due to any etiology other than AD (example, Parkinson's disease, cerebrovascular disease, normal pressure hydrocephalus, head injury, drug or alcohol abuse/dependence, anoxic brain injury, (Et cetera\[etc\])","NA","clinical_exam","must not"
"NCT04619420","exclusion","other","MCI diagnosis","NA","NA","NA","NA","NA","NA","Participants who fulfill diagnostic criteria for Mild Cognitive Impairment (MCI) or dementia/mild or major neurocognitive disorder suspected to be due to any etiology other than AD (example, Parkinson's disease, cerebrovascular disease, normal pressure hydrocephalus, head injury, drug or alcohol abuse/dependence, anoxic brain injury, (Et cetera\[etc\])","NA","clinical_exam","must not"
"NCT04619420","exclusion","lifestyle","Alcohol/substance use","NA","NA","NA","NA","NA","NA","Participants who fulfill diagnostic criteria for Mild Cognitive Impairment (MCI) or dementia/mild or major neurocognitive disorder suspected to be due to any etiology other than AD (example, Parkinson's disease, cerebrovascular disease, normal pressure hydrocephalus, head injury, drug or alcohol abuse/dependence, anoxic brain injury, (Et cetera\[etc\])","NA","questionnaire","must not"
"NCT04619420","exclusion","comorbidities","Geriatric Depression Scale","NA","NA","NA","NA","NA","NA","Geriatric Depression Scale (GDS) 30 score greater than (\>) 12","NA","questionnaire","must not"
"NCT04619420","exclusion","other","NA",">","4","NA","NA","NA","NA","Hachinski Ischemic Scale (HIS) \>4","NA","NA","must not"
"NCT04619420","exclusion","safety_labs","Safety labs/organ function","NA","NA","NA","NA","NA","NA","Has received medications that affect the central nervous system (CNS), except treatments for AD, for less than 2 months; that is, doses of chronic medications that effect the CNS should be stable for at least 2 months before the start of screening. If a participant has recently stopped a chronic medication that effects the CNS, he or she must have discontinued treatment at least 2 months before the start of screening. Chronic use of benzodiazepines is not permitted","stable for at least 2 months","lab_test","should"
"NCT04676360","inclusion","safety_labs","Safety labs/organ function","NA","NA","NA","NA","NA","NA","Participants must have relapsed or refractory plasmablastic lymphoma or ALK+ large Bcell lymphoma by WHO criteria.","NA","lab_test","must"
"NCT04676360","inclusion","safety_labs","Safety labs/organ function","NA","NA","NA","NA","NA","NA","Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter \[LDi\] to be recorded for non-nodal lesions and short axis for nodal lesions) as ≥15 mm in LDi for nodal disease or ≥10 mm in LDi for extranodal lesions.","NA","lab_test","must"
"NCT04676360","inclusion","safety_labs","Safety labs/organ function",">=","15","NA","mm","NA","NA","Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter \[LDi\] to be recorded for non-nodal lesions and short axis for nodal lesions) as ≥15 mm in LDi for nodal disease or ≥10 mm in LDi for extranodal lesions.","NA","lab_test","must"
"NCT04676360","inclusion","other","NA","NA","NA","NA","NA","NA","NA","Participants must have received prior systemic lymphoma therapy.","NA","NA","must"
"NCT04676360","inclusion","demographics","Age","between","18","18","years","NA","NA","Age ≥18 years. Because no dosing or adverse event data are currently available on the use of belantamab mafodotin in participants \<18 years of age, children are excluded from this study.","NA","NA","must"
"NCT04676360","inclusion","other","NA","between","60","2","NA","NA","NA","ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A).","NA","NA","must"
"NCT04676360","inclusion","other","NA","NA","NA","NA","NA","NA","NA","Participants must have adequate marrow function as defined below (unless abnormalities are considered related to marrow and/or splenic involvement by lymphoma):","NA","NA","must"
"NCT04676360","inclusion","other","NA",">=","1","NA","NA","NA","NA","absolute neutrophil count ≥1,000/mcL","NA","NA","must"
"NCT04676360","inclusion","safety_labs","Safety labs/organ function",">=","50","NA","NA","NA","NA","platelets ≥50,000/mcL","NA","lab_test","must"
"NCT04676360","inclusion","other","NA",">=","8.0","NA","NA","NA","NA","hemoglobin ≥ 8.0 g/dL","NA","NA","must"
"NCT04676360","inclusion","other","NA","NA","NA","NA","NA","NA","NA","Participants must have adequate organ function as defined below:","NA","NA","must"
"NCT04676360","inclusion","safety_labs","Safety labs/organ function","between","1.5","1.5","xULN","NA","NA","total bilirubin ≤ 1.5 X institutional upper limit of normal (ULN); (Isolated bilirubin ≥1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%)","NA","lab_test","must"
"NCT04676360","inclusion","safety_labs","Safety labs/organ function","<","NA","35","NA","NA","NA","total bilirubin ≤ 1.5 X institutional upper limit of normal (ULN); (Isolated bilirubin ≥1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%)","NA","lab_test","must"
"NCT04676360","inclusion","safety_labs","Safety labs/organ function","<=","NA","2.5","xULN","NA","NA","AST(SGOT)/ALT(SGPT) ≤2.5 × institutional ULN","NA","lab_test","must"
"NCT04676360","inclusion","safety_labs","Safety labs/organ function","<","NA","500","mg","NA","NA","Spot urine (albumin/creatinine) \<500 mg/g (56 mg/mmol) OR","NA","lab_test","must"
"NCT04676360","inclusion","safety_labs","Safety labs/organ function","between","1","500","mg","NA","NA","Urine Dipstick Negative/trace (if ≥1+ only eligible if confirmed ≤ 500 mg/g (56 mg/mmol) by albumin/creatinine ratio (spot urine from first void)","NA","lab_test","must"
"NCT04676360","inclusion","other","NA",">=","30","NA","NA","NA","NA","Glomerular filtration rate (eGFR)≥30 mL/min/1.73 m2 (MDRD Formula).","NA","NA","must"
"NCT04676360","inclusion","other","NA","history/presence of","NA","NA","NA","NA","NA","Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, participants should be class 2B or better.","NA","NA","should"
"NCT04676360","inclusion","demographics","Sex/pregnancy","NA","NA","NA","NA","NA","NA","Belantamab mafodotin is potentially teratogenic. A female participant is eligible to participate if she is not pregnant or breastfeeding. Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for at least 4 months after the last dose of study intervention. Women must also agree not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Nonchildbearing potential is defined as follows (by other than medical reasons):","NA","NA","must"
"NCT04676360","inclusion","demographics","Sex/pregnancy","NA","NA","NA","NA","NA","NA","Belantamab mafodotin is potentially teratogenic. A female participant is eligible to participate if she is not pregnant or breastfeeding. Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for at least 4 months after the last dose of study intervention. Women must also agree not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Nonchildbearing potential is defined as follows (by other than medical reasons):","NA","NA","must"
"NCT04676360","inclusion","demographics","Sex/pregnancy","NA","NA","NA","NA","NA","NA","Belantamab mafodotin is potentially teratogenic. A female participant is eligible to participate if she is not pregnant or breastfeeding. Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for at least 4 months after the last dose of study intervention. Women must also agree not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Nonchildbearing potential is defined as follows (by other than medical reasons):","NA","NA","must"
"NCT04676360","inclusion","demographics","Sex/pregnancy","agree not to","NA","NA","NA","NA","NA","Belantamab mafodotin is potentially teratogenic. A female participant is eligible to participate if she is not pregnant or breastfeeding. Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for at least 4 months after the last dose of study intervention. Women must also agree not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Nonchildbearing potential is defined as follows (by other than medical reasons):","NA","NA","must"
"NCT04676360","inclusion","demographics","Sex/pregnancy","NA","NA","NA","NA","NA","NA","Belantamab mafodotin is potentially teratogenic. A female participant is eligible to participate if she is not pregnant or breastfeeding. Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for at least 4 months after the last dose of study intervention. Women must also agree not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Nonchildbearing potential is defined as follows (by other than medical reasons):","NA","NA","must"
"NCT04676360","inclusion","demographics","Sex/pregnancy","NA","NA","NA","NA","NA","NA","Belantamab mafodotin is potentially teratogenic. A female participant is eligible to participate if she is not pregnant or breastfeeding. Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for at least 4 months after the last dose of study intervention. Women must also agree not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Nonchildbearing potential is defined as follows (by other than medical reasons):","NA","NA","must"
"NCT04676360","inclusion","demographics","Age",">=","45","NA","years","NA","NA","≥45 years of age and has not had menses for \>1 year","NA","NA","must"
"NCT04676360","inclusion","demographics","Age",">","1","NA","years","NA","NA","≥45 years of age and has not had menses for \>1 year","NA","NA","must"
"NCT04676360","inclusion","demographics","Age","<","NA","2","years","NA","NA","Patients who have been amenorrhoeic for \<2 years without history of a hysterectomy and oophorectomy must have a follicle stimulating hormone value in the postmenopausal range upon screening evaluation","NA","NA","must"
"NCT04676360","inclusion","demographics","Age","NA","NA","NA","NA","NA","NA","Patients who have been amenorrhoeic for \<2 years without history of a hysterectomy and oophorectomy must have a follicle stimulating hormone value in the postmenopausal range upon screening evaluation","NA","NA","must"
"NCT04676360","inclusion","other","NA","NA","NA","NA","NA","NA","NA","Post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation. Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound. Tubal ligation must be confirmed with medical records of the actual procedure.","NA","NA","must"
"NCT04676360","inclusion","demographics","Sex/pregnancy","negative","NA","NA","NA","NA","NA","Women of childbearing potential must have a negative highly sensitive serum pregnancy test, and agree to repeat highly sensitive serum pregnancy testing within 72 hours before the first dose of study intervention (if screening pregnancy test was not within 72 hours of dosing).","NA","NA","must"
"NCT04676360","inclusion","demographics","Sex/pregnancy","NA","NA","NA","NA","NA","NA","Women of childbearing potential must have a negative highly sensitive serum pregnancy test, and agree to repeat highly sensitive serum pregnancy testing within 72 hours before the first dose of study intervention (if screening pregnancy test was not within 72 hours of dosing).","NA","NA","must"
"NCT04676360","inclusion","demographics","Sex/pregnancy","NA","NA","NA","NA","NA","NA","Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of administration. Men must also agree not to donate sperm during this period. Men may agree to remain abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) OR agree to use a male condom, even if they have undergone a successful vasectomy and female partner to use an additional highly effective contraceptive method with a failure rate of \<1% per year when having sexual intercourse with a WOCBP (including pregnant females).","NA","NA","must"
"NCT04676360","inclusion","study_operations","Reproductive/blood donation","NA","NA","NA","NA","NA","NA","Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of administration. Men must also agree not to donate sperm during this period. Men may agree to remain abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) OR agree to use a male condom, even if they have undergone a successful vasectomy and female partner to use an additional highly effective contraceptive method with a failure rate of \<1% per year when having sexual intercourse with a WOCBP (including pregnant females).","NA","NA","must"
"NCT04676360","inclusion","demographics","Sex/pregnancy","agree not to","NA","NA","NA","NA","NA","Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of administration. Men must also agree not to donate sperm during this period. Men may agree to remain abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) OR agree to use a male condom, even if they have undergone a successful vasectomy and female partner to use an additional highly effective contraceptive method with a failure rate of \<1% per year when having sexual intercourse with a WOCBP (including pregnant females).","NA","NA","must"
"NCT04676360","inclusion","study_operations","Reproductive/blood donation","NA","NA","NA","NA","NA","NA","Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of administration. Men must also agree not to donate sperm during this period. Men may agree to remain abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) OR agree to use a male condom, even if they have undergone a successful vasectomy and female partner to use an additional highly effective contraceptive method with a failure rate of \<1% per year when having sexual intercourse with a WOCBP (including pregnant females).","NA","NA","must"
"NCT04676360","inclusion","demographics","Sex/pregnancy","NA","NA","NA","NA","NA","NA","Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of administration. Men must also agree not to donate sperm during this period. Men may agree to remain abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) OR agree to use a male condom, even if they have undergone a successful vasectomy and female partner to use an additional highly effective contraceptive method with a failure rate of \<1% per year when having sexual intercourse with a WOCBP (including pregnant females).","NA","NA","must"
"NCT04676360","inclusion","demographics","Age","<","NA","1","years","NA","NA","Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of administration. Men must also agree not to donate sperm during this period. Men may agree to remain abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) OR agree to use a male condom, even if they have undergone a successful vasectomy and female partner to use an additional highly effective contraceptive method with a failure rate of \<1% per year when having sexual intercourse with a WOCBP (including pregnant females).","NA","NA","must"
"NCT04676360","inclusion","comorbidities","Stroke/TIA history","history/presence of","NA","NA","NA","NA","NA","Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial at the discretion of the overall PI.","NA","clinical_exam","must"
"NCT04676360","inclusion","study_operations","Informed consent","consent to","NA","NA","NA","NA","NA","Ability to understand and the willingness to sign a written informed consent document.","NA","NA","must"
"NCT04676360","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Participants must not have current corneal epithelial disease except mild changes in corneal epithelium.","NA","NA","must not"
"NCT04676360","exclusion","safety_labs","Safety labs/organ function","history/presence of","NA","NA","NA","NA","NA","Participant must not have current unstable liver or biliary disease defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis. Note: Stable non cirrhotic chronic liver disease (including Gilbert's syndrome or asymptomatic gallstones) or hepatobiliary involvement of malignancy is acceptable if otherwise meets entry criteria.","NA","lab_test","must not"
"NCT04676360","exclusion","comorbidities","Malignancy","NA","NA","NA","NA","NA","NA","Participants who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \> Grade 1) with the exception of alopecia. At the discretion of the overall PI, participants with residual toxicities \> Grade 1 may be considered eligible if in the opinion of the overall PI the residual toxicity is not likely to interfere with the safety or efficacy assessment of the investigational regimen.","NA","clinical_exam","may"
"NCT04676360","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Participants who are receiving any other investigational agents.","NA","NA","must not"
"NCT04676360","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Participants must not have central nervous system involvement by lymphoma, as belantamab mafodotin is not known to penetrate the CNS.","NA","NA","must not"
"NCT04676360","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Participant must not use contact lenses while participating in this study.","NA","NA","must not"
"NCT04676360","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Participant must not be simultaneously enrolled in any interventional clinical trial.","NA","NA","must not"
"NCT04676360","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Participant must not have used an investigational drug or approved systemic lymphoma therapy within 14 days or five half-lives, whichever is shorter, preceding the first dose of study drug. Steroids are permitted.","NA","NA","must not"
"NCT04676360","exclusion","comorbidities","Stroke/TIA history","NA","NA","NA","NA","NA","NA","Participant must not have had major surgery within 4 weeks of initiating study treatment.","NA","clinical_exam","must not"
"NCT04676360","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Participant must not have any evidence of active mucosal or internal bleeding.","NA","NA","must not"
"NCT04676360","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Participants must not have known immediate or delayed hypersensitivity reaction or idiosyncratic reactions to belantamab mafodotin or drugs chemically related to belantamab mafodotin, or any of the components of the study treatment.","NA","NA","must not"
"NCT04676360","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Participants must not have an uncontrolled intercurrent illness.","NA","NA","must not"
"NCT04676360","exclusion","comorbidities","CNS infection history","NA","NA","NA","NA","NA","NA","Participant must not have an uncontrolled active infection.","NA","clinical_exam","must not"
"NCT04676360","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Participant must not have evidence of cardiovascular risk including any of the following:","NA","NA","must not"
"NCT04676360","exclusion","other","NA","history/presence of","NA","NA","NA","NA","NA","Evidence of current clinically significant uncontrolled arrhythmias, including clinically significant ECG abnormalities such as 2nd degree (Mobitz Type II) or 3rd degree atrioventricular (AV) block.","NA","NA","must not"
"NCT04676360","exclusion","safety_labs","Safety labs/organ function","history/presence of","NA","NA","NA","NA","NA","History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting/bypass grafting within three (3) months of Screening.","NA","lab_test","must not"
"NCT04676360","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Class III or IV heart failure as defined by the New York Heart Association functional classification system \[NYHA, 1994\].","NA","NA","must not"
"NCT04676360","exclusion","safety_labs","Safety labs/organ function",">","160","NA","NA","NA","NA","Participant must not have uncontrolled hypertension defined as persistent systolic BP \>160 mmHg or diastolic BP \>100 mmHg.","NA","lab_test","must not"
"NCT04676360","exclusion","comorbidities","Psychiatric disorder history","NA","NA","NA","NA","NA","NA","Participant must not have psychiatric illness/social situations that would limit compliance with study requirements. Participants must not have any serious and/or pre-existing medical or other condition (including lab abnormalities) that could interfere with participant's safety in the opinion of the investigator.","NA","clinical_exam","must not"
"NCT04676360","exclusion","demographics","Sex/pregnancy","NA","NA","NA","NA","NA","NA","Women who are pregnant or lactating are excluded from this study because belantamab mafodotin can cause embryo-fetal harm when administered to a pregnant woman. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with belantamab mafodotin, breastfeeding should be discontinued if the mother is treated with belantamab mafodotin.","NA","NA","should"
"NCT04676360","exclusion","demographics","Sex/pregnancy","NA","NA","NA","NA","NA","NA","Women who are pregnant or lactating are excluded from this study because belantamab mafodotin can cause embryo-fetal harm when administered to a pregnant woman. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with belantamab mafodotin, breastfeeding should be discontinued if the mother is treated with belantamab mafodotin.","NA","NA","should"
"NCT04676360","exclusion","other","NA","positive","NA","NA","NA","NA","NA","Participant must not have presence of hepatitis B surface antigen (HBsAg), or hepatitis B core antibody (HBcAb) at screening or within 3 months prior to first dose of study treatment. Patients with presence of HBsAg, but demonstrate both HBSag and HBV PCR negativity will be eligible for the study. Participant must not have positive hepatitis C antibody test result or positive hepatitis C RNA test result at screening or within 3 months prior to first dose of study treatment. Note: Participants with positive Hepatitis C antibody due to prior resolved disease can be enrolled, only if a confirmatory negative Hepatitis C RNA test is obtained. Note: Hepatitis RNA testing is optional and participants with negative Hepatitis C antibody test are not required to also undergo Hepatitis C RNA testing.","at screening","NA","must not"
"NCT04676360","exclusion","comorbidities","HIV infection","NA","NA","NA","NA","NA","NA","Participant must not have uncontrolled HIV infection. HIV-infected patients on effective anti-retroviral therapy are eligible if they (1) have an undetectable viral load within the prior 6 months, or (2) have a detectable viral load with an absolute CD4 count of 200 cells per microliter or higher.","NA","lab_test","must not"
"NCT04676360","exclusion","comorbidities","HIV infection","NA","NA","NA","NA","NA","NA","Participant must not have uncontrolled HIV infection. HIV-infected patients on effective anti-retroviral therapy are eligible if they (1) have an undetectable viral load within the prior 6 months, or (2) have a detectable viral load with an absolute CD4 count of 200 cells per microliter or higher.","NA","lab_test","must not"
"NCT04676360","exclusion","comorbidities","HIV infection","NA","NA","NA","NA","NA","NA","Participant must not have uncontrolled HIV infection. HIV-infected patients on effective anti-retroviral therapy are eligible if they (1) have an undetectable viral load within the prior 6 months, or (2) have a detectable viral load with an absolute CD4 count of 200 cells per microliter or higher.","NA","lab_test","must not"
"NCT04676360","exclusion","demographics","Age","NA","NA","NA","NA","NA","NA","Participant must not have invasive malignancies other than disease under study, unless the second malignancy has been medically stable for at least 2 years and, in the opinion of the principal investigators, will not affect the evaluation of the effects of clinical trial treatments on the currently targeted malignancy. Participants with adequately treated basal, squamous cell carcinoma or non-melanomatous skin cancer, carcinoma in situ of the cervix, superficial bladder cancer not treated with intravesical chemotherapy or BCG within 6 months, localized prostate cancer and PSA \<1.0 mg/dL on 2 consecutive measurements at least 3 months apart with the most recent one being within 4 weeks of study entry, may be enrolled without a 2-year restriction.","stable for at least 2 years","NA","must not"
"NCT04676360","exclusion","comorbidities","Malignancy","NA","NA","NA","NA","NA","NA","Participant must not have invasive malignancies other than disease under study, unless the second malignancy has been medically stable for at least 2 years and, in the opinion of the principal investigators, will not affect the evaluation of the effects of clinical trial treatments on the currently targeted malignancy. Participants with adequately treated basal, squamous cell carcinoma or non-melanomatous skin cancer, carcinoma in situ of the cervix, superficial bladder cancer not treated with intravesical chemotherapy or BCG within 6 months, localized prostate cancer and PSA \<1.0 mg/dL on 2 consecutive measurements at least 3 months apart with the most recent one being within 4 weeks of study entry, may be enrolled without a 2-year restriction.","stable for at least 2 years","clinical_exam","must not"
"NCT04676360","exclusion","comorbidities","Malignancy","NA","NA","NA","NA","NA","NA","Participant must not have invasive malignancies other than disease under study, unless the second malignancy has been medically stable for at least 2 years and, in the opinion of the principal investigators, will not affect the evaluation of the effects of clinical trial treatments on the currently targeted malignancy. Participants with adequately treated basal, squamous cell carcinoma or non-melanomatous skin cancer, carcinoma in situ of the cervix, superficial bladder cancer not treated with intravesical chemotherapy or BCG within 6 months, localized prostate cancer and PSA \<1.0 mg/dL on 2 consecutive measurements at least 3 months apart with the most recent one being within 4 weeks of study entry, may be enrolled without a 2-year restriction.","stable for at least 2 years","clinical_exam","must not"
"NCT04676360","exclusion","demographics","Age","<","NA","1.0","years","NA","NA","Participant must not have invasive malignancies other than disease under study, unless the second malignancy has been medically stable for at least 2 years and, in the opinion of the principal investigators, will not affect the evaluation of the effects of clinical trial treatments on the currently targeted malignancy. Participants with adequately treated basal, squamous cell carcinoma or non-melanomatous skin cancer, carcinoma in situ of the cervix, superficial bladder cancer not treated with intravesical chemotherapy or BCG within 6 months, localized prostate cancer and PSA \<1.0 mg/dL on 2 consecutive measurements at least 3 months apart with the most recent one being within 4 weeks of study entry, may be enrolled without a 2-year restriction.","stable for at least 2 years","NA","must not"
"NCT04676360","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Participant must not have had plasmapheresis within 7 days prior to first dose of study treatment","within 7 days prior","NA","must not"
"NCT04676360","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Participant must not have received prior treatment with a monoclonal antibody within 30 days of receiving the first dose of study drugs","NA","NA","must not"
"NCT04770220","inclusion","other","MCI diagnosis","history/presence of","NA","NA","NA","NIA-AA","MCI due to AD","Clinical diagnosis of MCI or Mild Dementia due to AD consistent with the National Institute on Aging-Alzheimer's Association (NIA-AA) Working Group Criteria.","NA","clinical_exam","must"
"NCT04770220","inclusion","other","AD dementia diagnosis","NA","NA","NA","NA","NIA-AA","MCI due to AD","Clinical diagnosis of MCI or Mild Dementia due to AD consistent with the National Institute on Aging-Alzheimer's Association (NIA-AA) Working Group Criteria.","NA","clinical_exam","must"
"NCT04770220","inclusion","genetics","APOE genotype","NA","NA","NA","NA","NA","NA","Homozygous for the ε4 allele of the apolipoprotein E gene (APOE4/4).","NA","genetic_test","must"
"NCT04770220","inclusion","cognition","MMSE","between","22","30","score","NA","NA","MMSE score at Screening of 22 to 30 (inclusive).","at screening","cognitive_test","must"
"NCT04770220","inclusion","global_impairment","CDR global score","in","0.5","1","score","NA","NA","CDR - Global score of 0.5 or 1 and CDR Memory Box Score of ≥ 0.5.","NA","clinical_exam","must"
"NCT04770220","inclusion","global_impairment","CDR Memory Box score",">=","0.5","NA","score","NA","NA","CDR - Global score of 0.5 or 1 and CDR Memory Box Score of ≥ 0.5.","NA","clinical_exam","must"
"NCT04770220","inclusion","cognition","RBANS","<=","NA","85","score","NA","NA","RBANS delayed memory index score ≤ 85.","NA","cognitive_test","must"
"NCT04770220","inclusion","safety_labs","Safety labs/organ function","NA","NA","NA","NA","NA","NA","Evidence of progressive memory loss over the last 12 months per investigator assessment","over the last 12 months","lab_test","must"
"NCT04770220","exclusion","imaging","Brain MRI","NA","NA","NA","NA","NA","NA","Brain magnetic resonance imaging (MRI) indicative of significant abnormality per central reader, other than AD related atrophy. Computed tomography (CT) scan acceptable for subjects who cannot undergo MRI.","NA","MRI","must not"
"NCT04770220","exclusion","other","NA","history/presence of","NA","NA","NA","NA","NA","Diagnosis of neurodegenerative disorder other than AD.","NA","NA","must not"
"NCT04770220","exclusion","demographics","Age","history/presence of","NA","NA","NA","NA","NA","Diagnosis of major depressive disorder (MDD) within one year prior to screening.","prior to screening","NA","must not"
"NCT04770220","exclusion","medications","Concomitant AD medications","NA","NA","NA","NA","NA","NA","Currently taking memantine or has taken memantine within 12 weeks prior to the Baseline Visit.","within 12 weeks prior","NA","must not"
"NCT04770220","exclusion","demographics","Age","history/presence of","NA","NA","NA","NA","NA","History of suicidal behavior within one year prior to screening or has ongoing suicidal ideation.","prior to screening","NA","must not"
"NCT04770220","exclusion","comorbidities","Seizure history","history/presence of","NA","NA","NA","NA","NA","History of seizures, excluding febrile seizures of childhood or a single distant seizure (\> 5 years).","NA","clinical_exam","must not"
"NCT04770220","exclusion","demographics","Age",">","5","NA","years","NA","NA","History of seizures, excluding febrile seizures of childhood or a single distant seizure (\> 5 years).","NA","NA","must not"
"NCT04770220","exclusion","comorbidities","Stroke/TIA history","history/presence of","NA","NA","NA","NA","NA","Medically confirmed history of recent cerebral infarct or transient ischemic attack within one year prior to screening.","prior to screening","clinical_exam","must not"
"NCT04770220","exclusion","demographics","Age","NA","NA","NA","NA","NA","NA","Medically confirmed history of recent cerebral infarct or transient ischemic attack within one year prior to screening.","prior to screening","NA","must not"
"NCT04777396","inclusion","demographics","Sex/pregnancy","NA","NA","NA","NA","NA","NA","Male or female, aged 55-85 years (both inclusive) at the time of signing informed consent.","NA","NA","must"
"NCT04777396","inclusion","demographics","Age","between","55","85","years","NA","NA","Male or female, aged 55-85 years (both inclusive) at the time of signing informed consent.","NA","NA","must"
"NCT04777396","inclusion","other","MCI diagnosis","NA","NA","NA","NA","NIA-AA","MCI due to AD","MCI (mild cognitive impairment) or mild dementia of the Alzheimer's type according to the NIA-AA (National Institute of Aging-Alzheimer's Association) 2018 criteria.","NA","clinical_exam","must"
"NCT04777396","inclusion","other","AD dementia diagnosis","NA","NA","NA","NA","NIA-AA","MCI due to AD","MCI (mild cognitive impairment) or mild dementia of the Alzheimer's type according to the NIA-AA (National Institute of Aging-Alzheimer's Association) 2018 criteria.","NA","clinical_exam","must"
"NCT04777396","inclusion","global_impairment","CDR global score","=","0.5","NA","score","NA","NA","CDR (Clinical Dementia Rating) global score of 0.5 and CDR of 0.5 or more in at least one of the three instrumental activities of daily living categories (personal care, home \& hobbies, community affairs) Or CDR global score of 1.0","NA","clinical_exam","must"
"NCT04777396","inclusion","daily_function","Activities of daily living",">=","0.5","NA","score","NA","NA","CDR (Clinical Dementia Rating) global score of 0.5 and CDR of 0.5 or more in at least one of the three instrumental activities of daily living categories (personal care, home \& hobbies, community affairs) Or CDR global score of 1.0","NA","questionnaire","must"
"NCT04777396","inclusion","global_impairment","CDR global score","=","1.0","NA","score","NA","NA","CDR (Clinical Dementia Rating) global score of 0.5 and CDR of 0.5 or more in at least one of the three instrumental activities of daily living categories (personal care, home \& hobbies, community affairs) Or CDR global score of 1.0","NA","clinical_exam","must"
"NCT04777396","inclusion","cognition","RBANS","NA","NA","NA","NA","NA","NA","RBANS (Repeatable Battery for the Assessment of Neuropsychological Status) delayed memory index score of below or equal to 85","NA","cognitive_test","must"
"NCT04777396","inclusion","cognition","RBANS","NA","NA","NA","NA","NA","NA","RBANS (Repeatable Battery for the Assessment of Neuropsychological Status) delayed memory index score of below or equal to 85","NA","cognitive_test","must"
"NCT04777396","inclusion","cognition","MMSE",">=","22","NA","score","NA","NA","MMSE (Mini-Mental State Examination) greater than or equal to 22","NA","cognitive_test","must"
"NCT04777396","inclusion","biomarkers","Amyloid pathology","positive","NA","NA","NA","NA","NA","Amyloid positivity established with either amyloid PET (positron emission tomography), CSF (cerebrospinal fluid) Aβ1-42 or CSF Aβ1-42/Aβ1-40 .","NA","NA","must"
"NCT04777396","inclusion","biomarkers","CSF biomarkers","NA","NA","NA","NA","NA","NA","Amyloid positivity established with either amyloid PET (positron emission tomography), CSF (cerebrospinal fluid) Aβ1-42 or CSF Aβ1-42/Aβ1-40 .","NA","CSF","must"
"NCT04777396","inclusion","medications","Concomitant AD medications","NA","NA","NA","NA","NA","NA","If receiving an approved Alzheimer's disease treatment (such as acetylcholinesterase inhibitors, memantine or aducanumab) the dose must have been stable for at least 3 months prior to screening and should not be changed during the trial unless medically necessary.","prior to screening","NA","must"
"NCT04777396","inclusion","medications","Concomitant AD medications","NA","NA","NA","NA","NA","NA","If receiving an approved Alzheimer's disease treatment (such as acetylcholinesterase inhibitors, memantine or aducanumab) the dose must have been stable for at least 3 months prior to screening and should not be changed during the trial unless medically necessary.","prior to screening","NA","must"
"NCT04777396","inclusion","medications","Concomitant AD medications","NA","NA","NA","NA","NA","NA","If receiving an approved Alzheimer's disease treatment (such as acetylcholinesterase inhibitors, memantine or aducanumab) the dose must have been stable for at least 3 months prior to screening and should not be changed during the trial unless medically necessary.","prior to screening","NA","must"
"NCT04777396","exclusion","imaging","Brain MRI","history/presence of","NA","NA","NA","NA","NA","Brain MRI (or CT) scan suggestive of clinically significant structural CNS disease confirmed by central read (e.g. cerebral large-vessel disease \[large vessel (cortical) infarcts greater than 10 mm in diameter\], prior macro-haemorrhage \[greater than 1 cm\^3\], cerebral vascular malformations, cortical hemosiderosis, intracranial aneurism(s), intracranial tumours, changes suggestive of normal pressure hydrocephalus).","NA","MRI","must not"
"NCT04777396","exclusion","imaging","Brain MRI","NA","NA","NA","NA","NA","NA","Brain MRI (magnetic resonance imaging) (or CT) scan suggestive of significant small vessel pathology confirmed by central read and defined as greater than1 lacunar infarct and/or ARWMC (age-related white matter changes) greater than 2, (WM (white matter) greater than 20 mm) in the deep white matter and periventricular regions.","NA","MRI","must not"
"NCT04777396","exclusion","demographics","Age","NA","NA","NA","NA","NA","NA","Brain MRI (magnetic resonance imaging) (or CT) scan suggestive of significant small vessel pathology confirmed by central read and defined as greater than1 lacunar infarct and/or ARWMC (age-related white matter changes) greater than 2, (WM (white matter) greater than 20 mm) in the deep white matter and periventricular regions.","NA","MRI","must not"
"NCT04777396","exclusion","imaging","Brain MRI","NA","NA","NA","NA","NA","NA","Brain MRI (magnetic resonance imaging) (or CT) scan suggestive of significant small vessel pathology confirmed by central read and defined as greater than1 lacunar infarct and/or ARWMC (age-related white matter changes) greater than 2, (WM (white matter) greater than 20 mm) in the deep white matter and periventricular regions.","NA","MRI","must not"
"NCT04777396","exclusion","imaging","Brain MRI","NA","NA","NA","NA","NA","NA","Brain MRI (or CT) scan suggestive of strategic infarcts defined as bilateral thalamic lacunar infarcts and singular paramedian thalamic infarcts confirmed by central read.","NA","MRI","must not"
"NCT04777396","exclusion","imaging","Brain MRI","NA","NA","NA","NA","NA","NA","Brain MRI (or CT) scan suggestive of strategic infarcts defined as bilateral thalamic lacunar infarcts and singular paramedian thalamic infarcts confirmed by central read.","NA","MRI","must not"
"NCT04777396","exclusion","other","MCI diagnosis","NA","NA","NA","NA","NA","mild AD dementia","Evidence of a relevant neurological disorder other than MCI or mild dementia of the Alzheimer's type at screening, including but not limited to Parkinson's disease, Lewy body disease, frontotemporal dementia of any type, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, systemic lupus erythematosus, progressive supranuclear palsy, neurosyphilis, HIV (human immunodeficiency virus), learning disability, intellectual disability, hypoxic cerebral damage, or significant head trauma with loss of consciousness that led to persistent cognitive deficits","at screening","clinical_exam","must not"
"NCT04777396","exclusion","other","AD dementia diagnosis","NA","NA","NA","NA","NA","mild AD dementia","Evidence of a relevant neurological disorder other than MCI or mild dementia of the Alzheimer's type at screening, including but not limited to Parkinson's disease, Lewy body disease, frontotemporal dementia of any type, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, systemic lupus erythematosus, progressive supranuclear palsy, neurosyphilis, HIV (human immunodeficiency virus), learning disability, intellectual disability, hypoxic cerebral damage, or significant head trauma with loss of consciousness that led to persistent cognitive deficits","at screening","clinical_exam","must not"
"NCT04777396","exclusion","other","MCI diagnosis","NA","NA","NA","NA","NA","mild AD dementia","Evidence of a relevant neurological disorder other than MCI or mild dementia of the Alzheimer's type at screening, including but not limited to Parkinson's disease, Lewy body disease, frontotemporal dementia of any type, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, systemic lupus erythematosus, progressive supranuclear palsy, neurosyphilis, HIV (human immunodeficiency virus), learning disability, intellectual disability, hypoxic cerebral damage, or significant head trauma with loss of consciousness that led to persistent cognitive deficits","at screening","clinical_exam","must not"
"NCT04777396","exclusion","comorbidities","Psychiatric disorder history","NA","NA","NA","NA","DSM","NA","Evidence of a clinically relevant or unstable psychiatric disorder, based on Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria, including schizophrenia or other psychotic disorder, or bipolar disorder. A subject with a history of major depression who has not had an episode in the last 24 months before the day of screening and is considered in remission or whose depression is controlled with treatment can be included in the trial per investigator's judgement.","NA","clinical_exam","must not"
"NCT04777396","exclusion","comorbidities","Psychiatric disorder history","NA","NA","NA","NA","DSM","NA","Evidence of a clinically relevant or unstable psychiatric disorder, based on Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria, including schizophrenia or other psychotic disorder, or bipolar disorder. A subject with a history of major depression who has not had an episode in the last 24 months before the day of screening and is considered in remission or whose depression is controlled with treatment can be included in the trial per investigator's judgement.","NA","clinical_exam","must not"
"NCT04777396","exclusion","comorbidities","Psychiatric disorder history","NA","NA","NA","NA","DSM","NA","Evidence of a clinically relevant or unstable psychiatric disorder, based on Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria, including schizophrenia or other psychotic disorder, or bipolar disorder. A subject with a history of major depression who has not had an episode in the last 24 months before the day of screening and is considered in remission or whose depression is controlled with treatment can be included in the trial per investigator's judgement.","NA","clinical_exam","must not"
"NCT04777396","exclusion","safety_labs","Safety labs/organ function","history/presence of","NA","NA","NA","DSM","NA","Evidence of a clinically relevant or unstable psychiatric disorder, based on Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria, including schizophrenia or other psychotic disorder, or bipolar disorder. A subject with a history of major depression who has not had an episode in the last 24 months before the day of screening and is considered in remission or whose depression is controlled with treatment can be included in the trial per investigator's judgement.","NA","lab_test","must not"
"NCT04777396","exclusion","comorbidities","Psychiatric disorder history","NA","NA","NA","NA","DSM","NA","Evidence of a clinically relevant or unstable psychiatric disorder, based on Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria, including schizophrenia or other psychotic disorder, or bipolar disorder. A subject with a history of major depression who has not had an episode in the last 24 months before the day of screening and is considered in remission or whose depression is controlled with treatment can be included in the trial per investigator's judgement.","NA","clinical_exam","must not"
"NCT04828122","inclusion","imaging","Amyloid PET","NA","NA","NA","NA","NA","NA","Amyloid status must be known, based on an amyloid PET scan or CSF amyloid test, no older than 30 months at the time of consent for Arm 2 and Arm 4 participants (amyloid negative Arms).","no older than 30 months","PET","must"
"NCT04828122","inclusion","biomarkers","CSF biomarkers","consent to","NA","NA","NA","NA","NA","Amyloid status must be known, based on an amyloid PET scan or CSF amyloid test, no older than 30 months at the time of consent for Arm 2 and Arm 4 participants (amyloid negative Arms).","no older than 30 months","CSF","must"
"NCT04828122","inclusion","imaging","Amyloid PET","negative","NA","NA","NA","NA","NA","Amyloid status must be known, based on an amyloid PET scan or CSF amyloid test, no older than 30 months at the time of consent for Arm 2 and Arm 4 participants (amyloid negative Arms).","no older than 30 months","PET","must"
"NCT04828122","inclusion","imaging","Amyloid PET","NA","NA","NA","NA","NA","NA","Amyloid status must be known, based on an amyloid PET scan or CSF amyloid test, no older than 60 months at the time of consent for Arm 1 and Arm 3 (amyloid positive Arms).","no older than 60 months","PET","must"
"NCT04828122","inclusion","biomarkers","CSF biomarkers","consent to","NA","NA","NA","NA","NA","Amyloid status must be known, based on an amyloid PET scan or CSF amyloid test, no older than 60 months at the time of consent for Arm 1 and Arm 3 (amyloid positive Arms).","no older than 60 months","CSF","must"
"NCT04828122","inclusion","imaging","Amyloid PET","positive","NA","NA","NA","NA","NA","Amyloid status must be known, based on an amyloid PET scan or CSF amyloid test, no older than 60 months at the time of consent for Arm 1 and Arm 3 (amyloid positive Arms).","no older than 60 months","PET","must"
"NCT04828122","inclusion","demographics","Age","between","50","85","NA","NA","NA","Subjects must be aged 50-85 (inclusive).","NA","NA","must"
"NCT04828122","inclusion","cognition","MMSE","between","23","30","months","NA","NA","Subjects must have MMSE scores of 23-30 (inclusive) based on a test not older than 1 month at the time of the visit.","NA","cognitive_test","must"
"NCT04828122","inclusion","demographics","Age","consent to","NA","NA","NA","NA","NA","Date of diagnosis (if applicable) maximum of five years prior to consent.","prior to consent","NA","must"
"NCT04828122","inclusion","other","NA","NA","NA","NA","NA","NA","NA","Subjects' first language must be English.","NA","NA","must"
"NCT04828122","inclusion","other","NA","able/willing","NA","NA","NA","NA","NA","Willing to participate in a study investigating speech and Alzheimer's disease.","NA","NA","must"
"NCT04828122","inclusion","study_operations","Study partner","able/willing","NA","NA","NA","NA","NA","Availability of a person ('caregiver') who in the investigator's judgment has frequent and sufficient in-person contact with the participant, and is able to provide accurate information regarding the participant's cognitive and functional abilities. This is most likely met when living with a caregiver.","NA","NA","must"
"NCT04828122","inclusion","study_operations","Informed consent","consent to","NA","NA","NA","NA","NA","Able to provide valid informed consent","NA","NA","must"
"NCT04828122","inclusion","study_operations","Study partner","able/willing","NA","NA","NA","NA","NA","Able to use, or has a caregiver who is able to use a smartphone device.","NA","NA","must"
"NCT04828122","inclusion","other","NA","able/willing","NA","NA","NA","NA","NA","Has access to a smartphone device running an operation system of Android 7 or above; or iOS 11 or above.","NA","NA","must"
"NCT04828122","inclusion","study_operations","Study partner","able/willing","NA","NA","NA","NA","NA","Able to use, or has a caregiver who is able to use a personal computer, notebook or tablet.","NA","NA","must"
"NCT04828122","inclusion","other","NA",">=","12.04","NA","NA","NA","NA","Has access to a personal computing device of that is running an operating system of macOS X with macOS 10.9 or later, or Windows 7 or above, or Ubuntu 12.04 or higher; OR has access internet browser software Internet Explorer version 11 or above; or Microsoft Edge version 12 or above, or Firefox version 27 or above, or Google Chrome version 30 or above, or Safari version 7 or above; AND capable of audio and video recording; AND able to connect to the internet.","NA","NA","must"
"NCT04828122","exclusion","comorbidities","Psychiatric disorder history","history/presence of","NA","NA","NA","NA","NA","Clinically significant unstable psychiatric illness in 6 months.","NA","clinical_exam","must not"
"NCT04828122","exclusion","other","NA","history/presence of","NA","NA","NA","NA","NA","Diagnosis of Generalised Anxiety Disorder (GAD).","NA","NA","must not"
"NCT04828122","exclusion","other","NA","history/presence of","NA","NA","NA","NA","NA","Diagnosis of Major Depressive Disorder (MDD).","NA","NA","must not"
"NCT04828122","exclusion","demographics","Age","history/presence of","NA","NA","NA","NA","NA","History or presence of stroke within the past 2 years.","within the past 2 years","NA","must not"
"NCT04828122","exclusion","demographics","Age","history/presence of","NA","NA","NA","NA","NA","History or presence of stroke within the past 2 years.","within the past 2 years","NA","must not"
"NCT04828122","exclusion","comorbidities","Stroke/TIA history","history/presence of","NA","NA","NA","NA","NA","Documented history of transient ischemic attack or unexplained loss of consciousness within the last 12 months.","NA","clinical_exam","must not"
"NCT04828122","exclusion","safety_labs","Safety labs/organ function","NA","NA","NA","NA","NA","NA","Documented history of transient ischemic attack or unexplained loss of consciousness within the last 12 months.","NA","lab_test","must not"
"NCT04828122","exclusion","safety_labs","Safety labs/organ function","consent to","NA","NA","NA","NA","NA","The participant is using drugs to treat symptoms related to AD, and the doses of these drugs were not stable for at least 8 weeks prior to consent.","prior to consent","lab_test","must not"
"NCT05026866","inclusion","other","NA","NA","NA","NA","NA","NA","NA","A Telephone Interview for Cognitive Status - modified (TICS-M) score reflective of intact cognitive functioning.","NA","NA","must"
"NCT05026866","inclusion","biomarkers","Tau biomarkers","history/presence of","NA","NA","NA","NA","NA","Has a phosphorylated tau (P-tau) result consistent with the presence of amyloid pathology.","NA","CSF","must"
"NCT05026866","inclusion","study_operations","Study partner","NA","NA","NA","NA","NA","NA","Has a reliable study partner and backup study partner familiar with overall function and behavior, such as day-to-day activities and cognitive abilities.","NA","NA","must"
"NCT05026866","inclusion","comorbidities","Psychiatric disorder history","NA","NA","NA","NA","NA","NA","Have adequate literacy, vision, and hearing for neuropsychological testing at screening.","at screening","clinical_exam","must"
"NCT05026866","inclusion","demographics","Sex/pregnancy","NA","NA","NA","NA","NA","NA","Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies","NA","NA","should"
"NCT05026866","inclusion","demographics","Sex/pregnancy","NA","NA","NA","NA","NA","NA","Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies","NA","NA","should"
"NCT05026866","inclusion","demographics","Sex/pregnancy","NA","NA","NA","NA","NA","NA","Female participants include those who are infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy, or tubal ligation), congenital anomaly such as Mullerian agenesis; or post menopausal (women 55 or older not on hormone therapy and had at least 12 months of spontaneous amenorrhea; or with a diagnosis of menopause prior to starting hormone replacement therapy.","NA","NA","must"
"NCT05026866","inclusion","safety_labs","Safety labs/organ function","history/presence of","NA","NA","NA","NA","NA","Female participants include those who are infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy, or tubal ligation), congenital anomaly such as Mullerian agenesis; or post menopausal (women 55 or older not on hormone therapy and had at least 12 months of spontaneous amenorrhea; or with a diagnosis of menopause prior to starting hormone replacement therapy.","NA","lab_test","must"
"NCT05026866","inclusion","other","NA","NA","NA","NA","NA","NA","NA","Treatment Extension: (Study Period II Placebo Group Only)","NA","NA","must"
"NCT05026866","inclusion","other","NA","NA","NA","NA","NA","NA","NA","Are actively participating in Study AACM at the conclusion of Study Period III.","NA","NA","must"
"NCT05026866","exclusion","other","MCI diagnosis","NA","NA","NA","NA","NA","NA","Mild cognitive impairment or dementia, or significant other neurodegenerative disease that can affect cognition.","NA","clinical_exam","must not"
"NCT05026866","exclusion","comorbidities","Stroke/TIA history","NA","NA","NA","NA","NA","NA","Mild cognitive impairment or dementia, or significant other neurodegenerative disease that can affect cognition.","NA","clinical_exam","must not"
"NCT05026866","exclusion","other","MCI diagnosis","NA","NA","NA","NA","NA","NA","Mild cognitive impairment or dementia, or significant other neurodegenerative disease that can affect cognition.","NA","clinical_exam","must not"
"NCT05026866","exclusion","demographics","Age","NA","NA","NA","NA","NA","NA","Current serious or unstable illnesses including cardiovascular, hepatic, renal, gastroenterologic, respiratory, endocrinologic, neurologic, psychiatric, immunologic, or hematologic disease that could interfere with the analysis of the study or a life expectancy of approximately ≤5 years.","NA","NA","must not"
"NCT05026866","exclusion","safety_labs","Safety labs/organ function","NA","NA","NA","NA","NA","NA","Current serious or unstable illnesses including cardiovascular, hepatic, renal, gastroenterologic, respiratory, endocrinologic, neurologic, psychiatric, immunologic, or hematologic disease that could interfere with the analysis of the study or a life expectancy of approximately ≤5 years.","NA","lab_test","must not"
"NCT05026866","exclusion","demographics","Age","NA","NA","NA","NA","NA","NA","Current serious or unstable illnesses including cardiovascular, hepatic, renal, gastroenterologic, respiratory, endocrinologic, neurologic, psychiatric, immunologic, or hematologic disease that could interfere with the analysis of the study or a life expectancy of approximately ≤5 years.","NA","NA","must not"
"NCT05026866","exclusion","demographics","Age","<=","NA","5","years","NA","NA","Current serious or unstable illnesses including cardiovascular, hepatic, renal, gastroenterologic, respiratory, endocrinologic, neurologic, psychiatric, immunologic, or hematologic disease that could interfere with the analysis of the study or a life expectancy of approximately ≤5 years.","NA","NA","must not"
"NCT05026866","exclusion","comorbidities","Malignancy","history/presence of","NA","NA","NA","NA","NA","History of cancer with high risk of recurrence and preventing completion of the trial.","NA","clinical_exam","must not"
"NCT05026866","exclusion","other","NA","history/presence of","NA","NA","NA","NA","NA","History of clinically significant multiple or severe drug allergies, or severe posttreatment hypersensitivity reactions (including but not limited to erythema multiforme major, linear immunoglobulin A dermatosis, toxic epidermal necrolysis, and/or exfoliative dermatitis).","NA","NA","must not"
"NCT05026866","exclusion","imaging","Brain MRI","NA","NA","NA","NA","NA","NA","Have any clinically important abnormality at screening on magnetic resonance imaging (MRI) or clinical laboratory test results that could be detrimental to the participant or study integrity.","at screening","MRI","must not"
"NCT05026866","exclusion","imaging","Brain MRI","absent","NA","NA","NA","NA","NA","Have any contraindications for MRI, including claustrophobia or the presence of contraindicated metal (ferromagnetic) implants/cardiac pacemaker.","NA","MRI","must not"
"NCT05026866","exclusion","imaging","Brain MRI",">","4","NA","NA","NA","NA","Have a centrally read MRI demonstrating presence of amyloid-related imaging abnormalities (ARIA-E), \>4 cerebral microhemorrhages, more than 1 area of superficial siderosis, any macrohemorrhage or severe white matter disease at screening.","at screening","MRI","must not"
"NCT05026866","exclusion","other","NA","<","NA","5","NA","NA","NA","Have had prior treatment with a passive anti-amyloid immunotherapy \<5 half-lives prior to randomization.","NA","NA","must not"
"NCT05026866","exclusion","biomarkers","Amyloid beta (Aβ)","NA","NA","NA","NA","NA","NA","Have received active immunization against amyloid beta (Aβ) in any other study.","NA","CSF","must not"
"NCT05026866","exclusion","biomarkers","Amyloid beta (Aβ)","NA","NA","NA","NA","NA","NA","Have received active immunization against Aβ in any other study.","NA","CSF","must not"
"NCT05026866","exclusion","other","MCI diagnosis","NA","NA","NA","NA","NA","NA","Current or previous use of prescription medications used as treatment for mild cognitive impairment (MCI) or AD.","NA","clinical_exam","must not"
"NCT05026866","exclusion","imaging","PET imaging","absent","NA","NA","NA","NA","NA","Same as the main study except contraindications for florbetapir F 18 PET are exclusionary.","NA","PET","must not"
"NCT05108922","inclusion","study_operations","Study partner","NA","NA","NA","NA","NA","NA","Gradual and progressive change in memory function reported by the participant or informant for ≥6 months.","NA","NA","must"
"NCT05108922","inclusion","study_operations","Study partner",">=","6","NA","months","NA","NA","Gradual and progressive change in memory function reported by the participant or informant for ≥6 months.","NA","NA","must"
"NCT05108922","inclusion","imaging","PET imaging","NA","NA","NA","NA","NA","NA","Meet florbetapir F18 PET scan criteria.","NA","PET","must"
"NCT05108922","inclusion","global_impairment","CDR global score","NA","NA","NA","NA","NA","NA","A Clinical Dementia Rating (CDR)-Global Score of 0.5 or 1.","NA","clinical_exam","must"
"NCT05108922","inclusion","global_impairment","CDR global score","NA","NA","NA","NA","NA","NA","A Clinical Dementia Rating (CDR)-Global Score of 0.5 or 1.","NA","clinical_exam","must"
"NCT05108922","inclusion","genetics","APOE genotype","consent to","NA","NA","NA","NA","NA","Must consent to apolipoprotein E (ApoE) genotyping","NA","genetic_test","must"
"NCT05108922","inclusion","cognition","MMSE","between","20","30","score","NA","NA","Must have a mini mental state examination (MMSE) score between 20 and 30","NA","cognitive_test","must"
"NCT05108922","inclusion","study_operations","Study partner","consent to","NA","NA","NA","NA","NA","Have a study partner who will provide written informed consent to participate, is in frequent contact with the participant (defined as at least 10 hours per week), and will accompany the participant to study visits or be available by telephone at designated times.","NA","NA","must"
"NCT05108922","inclusion","study_operations","Study partner","NA","NA","NA","NA","NA","NA","Have a study partner who will provide written informed consent to participate, is in frequent contact with the participant (defined as at least 10 hours per week), and will accompany the participant to study visits or be available by telephone at designated times.","NA","NA","must"
"NCT05108922","inclusion","comorbidities","Psychiatric disorder history","NA","NA","NA","NA","NA","NA","Have adequate literacy, vision, and hearing for neuropsychological testing in the opinion of the investigator at the time of screening.","NA","clinical_exam","must"
"NCT05108922","inclusion","demographics","Sex/pregnancy","NA","NA","NA","NA","NA","NA","Women not of childbearing potential may participate","NA","NA","may"
"NCT05108922","exclusion","comorbidities","Stroke/TIA history","NA","NA","NA","NA","NA","NA","Significant neurological disease affecting the central nervous system (other than AD), that may affect cognition or ability to complete the study, including but not limited to, other dementias, serious infection of the brain, Parkinson's disease, multiple concussions, history of transient ischemic attack or stroke, or epilepsy or recurrent seizures (except febrile childhood seizures).","NA","clinical_exam","may"
"NCT05108922","exclusion","comorbidities","Stroke/TIA history","history/presence of","NA","NA","NA","NA","NA","Significant neurological disease affecting the central nervous system (other than AD), that may affect cognition or ability to complete the study, including but not limited to, other dementias, serious infection of the brain, Parkinson's disease, multiple concussions, history of transient ischemic attack or stroke, or epilepsy or recurrent seizures (except febrile childhood seizures).","NA","clinical_exam","may"
"NCT05108922","exclusion","comorbidities","Stroke/TIA history","NA","NA","NA","NA","NA","NA","Significant neurological disease affecting the central nervous system (other than AD), that may affect cognition or ability to complete the study, including but not limited to, other dementias, serious infection of the brain, Parkinson's disease, multiple concussions, history of transient ischemic attack or stroke, or epilepsy or recurrent seizures (except febrile childhood seizures).","NA","clinical_exam","may"
"NCT05108922","exclusion","comorbidities","Seizure history","NA","NA","NA","NA","NA","NA","Significant neurological disease affecting the central nervous system (other than AD), that may affect cognition or ability to complete the study, including but not limited to, other dementias, serious infection of the brain, Parkinson's disease, multiple concussions, history of transient ischemic attack or stroke, or epilepsy or recurrent seizures (except febrile childhood seizures).","NA","clinical_exam","may"
"NCT05108922","exclusion","comorbidities","Seizure history","NA","NA","NA","NA","NA","NA","Significant neurological disease affecting the central nervous system (other than AD), that may affect cognition or ability to complete the study, including but not limited to, other dementias, serious infection of the brain, Parkinson's disease, multiple concussions, history of transient ischemic attack or stroke, or epilepsy or recurrent seizures (except febrile childhood seizures).","NA","clinical_exam","may"
"NCT05108922","exclusion","safety_labs","Safety labs/organ function","NA","NA","NA","NA","NA","NA","Current serious or unstable medical illnesses including cardiovascular, hepatic, renal, gastroenterologic, respiratory, endocrinologic, psychiatric (including actively suicidal or deemed at risk of suicide, or current alcohol or substance abuse), immunologic, infectious, or hematologic disease and other conditions that, in the investigator's opinion, could interfere with the analyses in this study; or has a life expectancy of approximately","NA","lab_test","must not"
"NCT05108922","exclusion","safety_labs","Safety labs/organ function","NA","NA","NA","NA","NA","NA","Current serious or unstable medical illnesses including cardiovascular, hepatic, renal, gastroenterologic, respiratory, endocrinologic, psychiatric (including actively suicidal or deemed at risk of suicide, or current alcohol or substance abuse), immunologic, infectious, or hematologic disease and other conditions that, in the investigator's opinion, could interfere with the analyses in this study; or has a life expectancy of approximately","NA","lab_test","must not"
"NCT05108922","exclusion","safety_labs","Safety labs/organ function","history/presence of","NA","NA","NA","NA","NA","Current serious or unstable medical illnesses including cardiovascular, hepatic, renal, gastroenterologic, respiratory, endocrinologic, psychiatric (including actively suicidal or deemed at risk of suicide, or current alcohol or substance abuse), immunologic, infectious, or hematologic disease and other conditions that, in the investigator's opinion, could interfere with the analyses in this study; or has a life expectancy of approximately","NA","lab_test","must not"
"NCT05108922","exclusion","lifestyle","Alcohol/substance use","NA","NA","NA","NA","NA","NA","Current serious or unstable medical illnesses including cardiovascular, hepatic, renal, gastroenterologic, respiratory, endocrinologic, psychiatric (including actively suicidal or deemed at risk of suicide, or current alcohol or substance abuse), immunologic, infectious, or hematologic disease and other conditions that, in the investigator's opinion, could interfere with the analyses in this study; or has a life expectancy of approximately","NA","questionnaire","must not"
"NCT05108922","exclusion","lifestyle","Alcohol/substance use","NA","NA","NA","NA","NA","NA","Current serious or unstable medical illnesses including cardiovascular, hepatic, renal, gastroenterologic, respiratory, endocrinologic, psychiatric (including actively suicidal or deemed at risk of suicide, or current alcohol or substance abuse), immunologic, infectious, or hematologic disease and other conditions that, in the investigator's opinion, could interfere with the analyses in this study; or has a life expectancy of approximately","NA","questionnaire","must not"
"NCT05108922","exclusion","safety_labs","Safety labs/organ function","NA","NA","NA","NA","NA","NA","Current serious or unstable medical illnesses including cardiovascular, hepatic, renal, gastroenterologic, respiratory, endocrinologic, psychiatric (including actively suicidal or deemed at risk of suicide, or current alcohol or substance abuse), immunologic, infectious, or hematologic disease and other conditions that, in the investigator's opinion, could interfere with the analyses in this study; or has a life expectancy of approximately","NA","lab_test","must not"
"NCT05108922","exclusion","safety_labs","Safety labs/organ function","NA","NA","NA","NA","NA","NA","Current serious or unstable medical illnesses including cardiovascular, hepatic, renal, gastroenterologic, respiratory, endocrinologic, psychiatric (including actively suicidal or deemed at risk of suicide, or current alcohol or substance abuse), immunologic, infectious, or hematologic disease and other conditions that, in the investigator's opinion, could interfere with the analyses in this study; or has a life expectancy of approximately","NA","lab_test","must not"
"NCT05108922","exclusion","other","NA","<=","NA","24","months","NA","NA","≤24 months.","NA","NA","must not"
"NCT05108922","exclusion","other","NA","history/presence of","NA","NA","NA","NA","NA","History of clinically significant multiple or severe drug allergies, or severe posttreatment hypersensitivity reactions (including but not limited to erythema multiforme major, linear immunoglobulin A dermatosis, toxic epidermal necrolysis, and/or exfoliative dermatitis).","NA","NA","must not"
"NCT05108922","exclusion","medications","Anticoagulant/antiplatelet use","history/presence of","NA","NA","NA","NA","NA","History of bleeding disorder or use of medications with platelet anti-aggregant or anti-coagulant properties (unless aspirin at ≤325 milligram (mg).","NA","NA","must not"
"NCT05108922","exclusion","safety_labs","Safety labs/organ function","NA","NA","NA","NA","NA","NA","History of bleeding disorder or use of medications with platelet anti-aggregant or anti-coagulant properties (unless aspirin at ≤325 milligram (mg).","NA","lab_test","must not"
"NCT05108922","exclusion","medications","Anticoagulant/antiplatelet use","<=","NA","325","mg","NA","NA","History of bleeding disorder or use of medications with platelet anti-aggregant or anti-coagulant properties (unless aspirin at ≤325 milligram (mg).","NA","NA","must not"
"NCT05108922","exclusion","medications","Concomitant AD medications","NA","NA","NA","NA","NA","NA","Have had prior or current treatment with donanemab or aducanumab","NA","NA","must not"
"NCT05108922","exclusion","medications","Concomitant AD medications","NA","NA","NA","NA","NA","NA","Have known allergies to donanemab or aducanumab, related compounds, or any components of the formulation","NA","NA","must not"
"NCT05108922","exclusion","biomarkers","Amyloid beta (Aβ)","NA","NA","NA","NA","NA","NA","Prior or current participation in any immunotherapy study targeting Amyloid beta","NA","CSF","must not"
"NCT05194540","inclusion","demographics","Age","NA","NA","NA","NA","NA","NA","Age 12 years and above.","NA","NA","must"
"NCT05194540","inclusion","other","NA","able/willing","NA","NA","NA","NA","NA","Subject able and willing to self-administer tralokinumab with Device A.","NA","NA","must"
"NCT05194540","inclusion","other","NA","history/presence of","NA","NA","NA","NA","NA","Diagnosis of AD as defined by the Hanifin and Rajka (1980) criteria for AD.","NA","NA","must"
"NCT05194540","inclusion","demographics","Age",">=","1","NA","years","NA","NA","History of AD for ≥1 year.","NA","NA","must"
"NCT05194540","inclusion","demographics","Age","history/presence of","NA","NA","NA","NA","NA","A recent history (within 1 year before the screening visit) of inadequate response to treatment with topical medication or for whom topical treatments are otherwise medically inadvisable.","NA","NA","must"
"NCT05194540","inclusion","other","NA",">=","10","NA","NA","NA","NA","AD involvement of ≥10% body surface area at screening and baseline.","at screening","NA","must"
"NCT05194540","inclusion","other","NA","NA","NA","NA","NA","NA","NA","AD involvement of ≥10% body surface area at screening and baseline.","at screening","NA","must"
"NCT05194540","inclusion","other","NA",">=","12","NA","score","NA","NA","An EASI score of ≥12 at screening and ≥16 at baseline.","at screening","NA","must"
"NCT05194540","inclusion","other","NA",">=","16","NA","NA","NA","NA","An EASI score of ≥12 at screening and ≥16 at baseline.","at screening","NA","must"
"NCT05194540","inclusion","other","NA",">=","3","NA","score","NA","NA","An IGA score of ≥3 at screening and at baseline.","at screening","NA","must"
"NCT05194540","inclusion","other","NA","NA","NA","NA","NA","NA","NA","An IGA score of ≥3 at screening and at baseline.","at screening","NA","must"
"NCT05194540","inclusion","safety_labs","Safety labs/organ function","NA","NA","NA","NA","NA","NA","Applied a stable dose of emollient twice daily (or more, as needed) for at least 14 days before baseline.","NA","lab_test","must"
"NCT05194540","exclusion","other","NA","history/presence of","NA","NA","NA","NA","NA","Active dermatologic conditions that may confound the diagnosis of AD or would interfere with assessment of treatment.","NA","NA","may"
"NCT05194540","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Use of tanning beds or phototherapy within 4 weeks prior to baseline.","prior to baseline","NA","must not"
"NCT05194540","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Treatment with systemic immunosuppressive/immunomodulating drugs and/or systemic corticosteroids within 4 weeks prior to baseline.","prior to baseline","NA","must not"
"NCT05194540","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Treatment with topical corticosteroids, topical calcineurin inhibitors, topical phosphodiesterase 4 inhibitors, or topical Janus kinase inhibitors within 2 weeks prior to baseline.","prior to baseline","NA","must not"
"NCT05194540","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Receipt of any marketed biological therapy (i.e. immunoglobulin, anti immunoglobulin E) including dupilumab or investigational biologic agents 3 to 6 months prior to baseline.","prior to baseline","NA","must not"
"NCT05194540","exclusion","comorbidities","CNS infection history","NA","NA","NA","NA","NA","NA","Active skin infections within 1 week prior to baseline.","prior to baseline","clinical_exam","must not"
"NCT05194540","exclusion","comorbidities","CNS infection history","history/presence of","NA","NA","NA","NA","NA","Clinically significant infection within 4 weeks prior to baseline.","prior to baseline","clinical_exam","must not"
"NCT05194540","exclusion","study_operations","Informed consent","consent to","NA","NA","NA","NA","NA","A helminth parasitic infection within 6 months prior to the date informed consent is obtained.","within 6 months prior","NA","must not"
"NCT05194540","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Tuberculosis requiring treatment within 12 months prior to screening.","prior to screening","NA","must not"
"NCT05194540","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Known primary immunodeficiency disorder.","NA","NA","must not"
"NCT05269394","inclusion","demographics","Age","between","18","80","years","NA","NA","Between 18-80 years of age","NA","NA","must"
"NCT05269394","inclusion","other","NA","NA","NA","NA","NA","NA","NA","Individuals who know they have an Alzheimer's disease-causing mutation.","NA","NA","must"
"NCT05269394","inclusion","demographics","Age","NA","NA","NA","NA","NA","NA","Are within -10 to + 10 years of the predicted or actual age of cognitive symptom onset.","NA","NA","must"
"NCT05269394","inclusion","other","MCI diagnosis","NA","NA","NA","NA","NA","NA","Cognitively normal or with mild cognitive impairment or mild dementia, Clinical Dementia Rating (CDR) of 0-1 (inclusive)","NA","clinical_exam","must"
"NCT05269394","inclusion","other","MCI diagnosis","NA","NA","NA","NA","NA","NA","Cognitively normal or with mild cognitive impairment or mild dementia, Clinical Dementia Rating (CDR) of 0-1 (inclusive)","NA","clinical_exam","must"
"NCT05269394","inclusion","other","AD dementia diagnosis","between","0","1","score","NA","NA","Cognitively normal or with mild cognitive impairment or mild dementia, Clinical Dementia Rating (CDR) of 0-1 (inclusive)","NA","clinical_exam","must"
"NCT05269394","inclusion","other","NA","NA","NA","NA","NA","NA","NA","Fluency in DIAN-TU trial approved language and evidence of adequate premorbid intellectual functioning","NA","NA","must"
"NCT05269394","inclusion","imaging","PET imaging","able/willing","NA","NA","NA","NA","NA","Able to undergo Magnetic Resonance Imaging (MRI), Lumbar Puncture (LP), Positron Emission Tomography (PET), and complete all study related testing and evaluations.","NA","PET","must"
"NCT05269394","inclusion","imaging","PET imaging","NA","NA","NA","NA","NA","NA","Able to undergo Magnetic Resonance Imaging (MRI), Lumbar Puncture (LP), Positron Emission Tomography (PET), and complete all study related testing and evaluations.","NA","PET","must"
"NCT05269394","inclusion","imaging","PET imaging","NA","NA","NA","NA","NA","NA","Able to undergo Magnetic Resonance Imaging (MRI), Lumbar Puncture (LP), Positron Emission Tomography (PET), and complete all study related testing and evaluations.","NA","PET","must"
"NCT05269394","inclusion","demographics","Sex/pregnancy","NA","NA","NA","NA","NA","NA","For women of childbearing potential, if partner is not sterilized, participant must agree to use effective contraceptive measures (hormonal contraception, intra-uterine device, sexual abstinence, barrier method with spermicide).","NA","NA","must"
"NCT05269394","inclusion","other","NA","NA","NA","NA","NA","NA","NA","Adequate visual and auditory abilities to perform all aspects of the cognitive and functional assessments.","NA","NA","must"
"NCT05269394","inclusion","study_operations","Study partner","able/willing","NA","NA","NA","NA","NA","Has a Study Partner who in the investigator's judgment is able to provide accurate information as to the subject's cognitive and functional abilities, who agrees to provide information at the study visits which require informant input for scale completion.","NA","NA","must"
"NCT05269394","exclusion","comorbidities","Psychiatric disorder history","NA","NA","NA","NA","NA","NA","Significant neurologic disease (other than AD) or psychiatric disease that may currently or during the course of the study affect cognition or participant's ability to complete the study.","NA","clinical_exam","may"
"NCT05269394","exclusion","safety_labs","Safety labs/organ function","NA","NA","NA","NA","NA","NA","At high risk for suicide, e.g., significant suicidal ideation or attempt within last 12 months. Current stable mild depression or current use of antidepressant medications is not exclusionary.","NA","lab_test","must not"
"NCT05269394","exclusion","safety_labs","Safety labs/organ function","NA","NA","NA","NA","NA","NA","At high risk for suicide, e.g., significant suicidal ideation or attempt within last 12 months. Current stable mild depression or current use of antidepressant medications is not exclusionary.","NA","lab_test","must not"
"NCT05269394","exclusion","safety_labs","Safety labs/organ function","NA","NA","NA","NA","NA","NA","At high risk for suicide, e.g., significant suicidal ideation or attempt within last 12 months. Current stable mild depression or current use of antidepressant medications is not exclusionary.","NA","lab_test","must not"
"NCT05269394","exclusion","imaging","Brain MRI","history/presence of","NA","NA","NA","NA","NA","History or presence of brain MRI scans indicative of any other significant abnormality","NA","MRI","must not"
"NCT05269394","exclusion","demographics","Age","NA","NA","NA","NA","NA","NA","Substance or alcohol use disorder currently or within the past 1 year","within the past 1 year","NA","must not"
"NCT05269394","exclusion","lifestyle","Alcohol/substance use","NA","NA","NA","NA","NA","NA","Substance or alcohol use disorder currently or within the past 1 year","within the past 1 year","questionnaire","must not"
"NCT05269394","exclusion","demographics","Age","NA","NA","NA","NA","NA","NA","Substance or alcohol use disorder currently or within the past 1 year","within the past 1 year","NA","must not"
"NCT05269394","exclusion","imaging","Brain MRI","history/presence of","NA","NA","NA","NA","NA","Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, or foreign metal objects in the eyes, skin or body which would preclude MRI scan.","NA","MRI","must not"
"NCT05269394","exclusion","safety_labs","Safety labs/organ function","history/presence of","NA","NA","NA","NA","NA","History or presence of clinically significant cardiovascular disease, hepatic/renal disorders, infectious disease or immune disorder, or metabolic/endocrine disorders","NA","lab_test","must not"
"NCT05269394","exclusion","medications","Anticoagulant/antiplatelet use","<=","NA","325","mg","NA","NA","Anticoagulants except low dose (≤ 325 mg) aspirin.","NA","NA","must not"
"NCT05269394","exclusion","safety_labs","Safety labs/organ function","NA","NA","NA","NA","NA","NA","Have been exposed to a monoclonal antibody targeting beta amyloid peptide within the past six months.","NA","lab_test","must not"
"NCT05269394","exclusion","demographics","Age","history/presence of","NA","NA","NA","NA","NA","History of cancer within the last 5 years, except basal cell carcinoma, non-squamous skin carcinoma, prostate cancer or carcinoma in situ with no significant progression over the past 2 years.","NA","NA","must not"
"NCT05269394","exclusion","demographics","Age","NA","NA","NA","NA","NA","NA","History of cancer within the last 5 years, except basal cell carcinoma, non-squamous skin carcinoma, prostate cancer or carcinoma in situ with no significant progression over the past 2 years.","NA","NA","must not"
"NCT05269394","exclusion","demographics","Sex/pregnancy","positive","NA","NA","NA","NA","NA","Positive urine or serum pregnancy test or plans or desires to become pregnant during the course of the trial.","NA","NA","must not"
"NCT05269394","exclusion","imaging","Brain MRI","NA","NA","NA","NA","NA","NA","Subjects unable to complete all study related testing, including implanted metal that cannot be removed for MRI scanning, required anticoagulation and pregnancy.","NA","MRI","required"
"NCT05269394","exclusion","demographics","Sex/pregnancy","NA","NA","NA","NA","NA","NA","Subjects unable to complete all study related testing, including implanted metal that cannot be removed for MRI scanning, required anticoagulation and pregnancy.","NA","MRI","required"
"NCT05325008","inclusion","demographics","Age","NA","NA","NA","NA","NA","NA","Aged 2 years or above","NA","NA","must"
"NCT05325008","inclusion","safety_labs","Safety labs/organ function","NA","NA","NA","NA","NA","NA","Have received a kidney or simultaneous pancreas-kidney transplant","NA","lab_test","must"
"NCT05325008","inclusion","other","NA",">=","5","NA","weeks","NA","NA","Have BKPyV-Viremia (detected by RT-PCR) with a viral count ≥ 5,000 copies per mL, or histological confirmation of BKPyVAN, within 3 weeks prior to randomisation.","within 3 weeks prior","NA","must"
"NCT05325008","inclusion","study_operations","Informed consent","consent to","NA","NA","NA","NA","NA","Be able to provide informed consent or consent given by a parent or guardian (if age \<18 years) or other authorised person","NA","NA","must"
"NCT05325008","inclusion","demographics","Age","consent to","NA","NA","NA","NA","NA","Be able to provide informed consent or consent given by a parent or guardian (if age \<18 years) or other authorised person","NA","NA","must"
"NCT05325008","inclusion","demographics","Age","<","NA","18","years","NA","NA","Be able to provide informed consent or consent given by a parent or guardian (if age \<18 years) or other authorised person","NA","NA","must"
"NCT05325008","inclusion","demographics","Age","NA","NA","NA","NA","NA","NA","Be able to provide informed consent or consent given by a parent or guardian (if age \<18 years) or other authorised person","NA","NA","must"
"NCT05325008","exclusion","other","NA","absent","NA","NA","NA","NA","NA","Contraindications to receiving IVIG as a treatment","NA","NA","must not"
"NCT05325008","exclusion","other","NA","<=","NA","3","months","NA","NA","Current active acute rejection (≤ 3 months prior)","NA","NA","must not"
"NCT05325008","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Treating clinicians would regard as unsafe to be enrolled","NA","NA","must not"
"NCT05325008","exclusion","other","NA","<","NA","12","months","NA","NA","Limited life expectancy (\< 12 months)","NA","NA","must not"
"NCT05325008","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Receiving Belatacept as part of their immunosuppression protocol","NA","NA","must not"
"NCT05325008","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Currently undergoing or who have previously received, viral-specific T-cell therapy for BK viremia","NA","NA","must not"
"NCT05325008","exclusion","comorbidities","CNS infection history","NA","NA","NA","NA","NA","NA","Prior infection and treatment for BKPyV-Viremia","NA","clinical_exam","must not"
"NCT05325008","exclusion","safety_labs","Safety labs/organ function","<","NA","4","weeks","NA","NA","Received IVIG treatment in the past with last IVIG treatment \< 4 weeks prior to randomisation","NA","lab_test","must not"
"NCT05531656","inclusion","demographics","Age","between","50","85","years","NA","NA","Ages 50-85 years.","NA","NA","must"
"NCT05531656","inclusion","other","MCI diagnosis","history/presence of","NA","NA","NA","NA","MCI due to AD","Diagnosis of either MCI due to AD or mild AD dementia.","NA","clinical_exam","must"
"NCT05531656","inclusion","other","AD dementia diagnosis","NA","NA","NA","NA","NA","MCI due to AD","Diagnosis of either MCI due to AD or mild AD dementia.","NA","clinical_exam","must"
"NCT05531656","inclusion","cognition","MMSE","between","20","30","score","NA","NA","MMSE 20-30 (inclusive).","NA","cognitive_test","must"
"NCT05531656","inclusion","imaging","Amyloid PET","NA","NA","NA","NA","NA","NA","Amyloid PET scan of the brain or CSF biomarkers consistent with AD.","NA","PET","must"
"NCT05531656","inclusion","biomarkers","CSF biomarkers","NA","NA","NA","NA","NA","NA","Amyloid PET scan of the brain or CSF biomarkers consistent with AD.","NA","CSF","must"
"NCT05531656","inclusion","imaging","Brain MRI","history/presence of","NA","NA","NA","NA","NA","Neuroimaging (MRI) obtained during screening consistent with the clinical diagnosis of Alzheimer's disease, as based on central read.","NA","MRI","must"
"NCT05531656","exclusion","imaging","Brain MRI","NA","NA","NA","NA","NA","NA","Screening MRI of the brain indicative of significant abnormality.","NA","MRI","must not"
"NCT05531656","exclusion","other","NA","history/presence of","NA","NA","NA","NA","NA","Clinically significant abnormalities in screening laboratory tests.","NA","NA","must not"
"NCT05531656","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Clinical or laboratory findings consistent with:","NA","NA","must not"
"NCT05531656","exclusion","comorbidities","Stroke/TIA history","NA","NA","NA","NA","NA","NA","Other primary degenerative dementia, (dementia with Lewy bodies, fronto-temporal dementia, Huntington's disease, Creutzfeldt-Jakob Disease, Down syndrome, etc.).","NA","clinical_exam","must not"
"NCT05531656","exclusion","other","NA","NA","NA","NA","NA","NA","NA","Other neurodegenerative condition (Parkinson's disease, amyotrophic lateral sclerosis, etc.).","NA","NA","must not"
"NCT05531656","exclusion","safety_labs","Safety labs/organ function","NA","NA","NA","NA","NA","NA","Other infectious, metabolic or systemic diseases affecting the central nervous system (syphilis, present hypothyroidism, present vitamin B12, other laboratory values etc.)","NA","lab_test","must not"
"NCT05531656","exclusion","comorbidities","CNS infection history","negative","NA","NA","NA","NA","NA","A participant known to be actively infected with hepatitis B or hepatitis C at screening. History of acute/chronic hepatitis B or C and/or carriers of hepatitis B (seropositive for hepatitis B surface antigen \[HbsAg\] or anti-hepatitis C \[HCV\] antibody). Participants who have evidence of resolved hepatitis infection (e.g., HCV RNA negative) may be considered following discussion with the Medical Monitor.","at screening","clinical_exam","may"
"NCT05531656","exclusion","comorbidities","Psychiatric disorder history","history/presence of","NA","NA","NA","DSM","NA","A current DSM-V diagnosis of active major depression or GDS \> 6, schizophrenia, or bipolar disorder.","NA","clinical_exam","must not"
"NCT05531656","exclusion","comorbidities","Geriatric Depression Scale",">","6","NA","score","DSM","NA","A current DSM-V diagnosis of active major depression or GDS \> 6, schizophrenia, or bipolar disorder.","NA","questionnaire","must not"
"NCT05531656","exclusion","comorbidities","Psychiatric disorder history","NA","NA","NA","NA","DSM","NA","A current DSM-V diagnosis of active major depression or GDS \> 6, schizophrenia, or bipolar disorder.","NA","clinical_exam","must not"
